

# **SHREE GANESH BIO-TECH (INDIA) LIMITED**

CIN: L70101WB1982PLC121196

Reg. Office: CUBICLE NO.: 126, 3/2, 75C, PARK STREET, 3RD FLOOR KAMDHENU BUILDING, KOLKATA -700016

Email: shreeganeshbiotechindia ltd@gmail.com Website: www.shreeganeshbiotech.club

Date: 25.08.2025

To,  
Listing Department,  
BSE Limited,  
P J Tower, Dalal Street  
Mumbai-400001

To,  
The Secretary,  
The Calcutta Stock  
Exchange Ltd,  
7, Lyons Range,  
Kolkata - 700001

To,  
Head - Listing  
Metropolitan Stock Exchange of  
India Limited  
Vibgyor Towers, 4th floor, Plot No C  
62, Opp. Trident Hotel Bandra Kurla  
Complex, Bandra (E),  
Mumbai – 400098

Scrip Code: 539470

Scrip Code: 29221

Scrip Code: SHREEGANES

Dear Sir/Madam,

## **Sub: Submission of Annual Report for the Financial Year 2023-24**

Pursuant to Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting herewith the Annual Report of the Company for the financial year 2024-25 along with the Notice of 15<sup>th</sup> Annual General Meeting to be held on Friday 26<sup>th</sup> September, 2025.

Thanking you.

Yours faithfully

For, SHREE GANESH BIO-TECH (INDIA) LIMITED

Aman Patel  
Wholetime Director  
Encl.: As above.

# CORPORATE INFORMATION

## BOARD OF DIRECTORS:

AMAN PATEL	Wholetime Director
KISHAN NITYANAND NAIDU	Non-Executive Director
SOMBIR SINGH	Independent Director
HARSHAD RATHOD	Independent Director
AMRUTABEN SOLANKI	Independent Director
NIMESHKUMAR PARMAR	Independent Director
HARSHADKUMAR RATHOD	Independent Director

## KEY MANAGERIAL PERSONNEL:

KISHAN NITYANAND NAIDU	Chief Financial Officer
NAMITA ACHARYA	Company Secretary

## BOARD COMMITTEES:

### Audit:-

SOMBIR SINGH	Chairperson
NIMESH PARMAR	Member
AMRUTABEN SOLANKI	Member

### Nomination and Remuneration:-

SOMBIR SINGH	Chairperson
NIMESH PARMAR	Member
AMRUTABEN SOLANKI	Member

### Share Transfer and Grievances:-

AMRUTABEN SOLANKI	Chairperson
NIMESH PARMAR	Member
SOMBIR SINGH	Member

### Listing Details:-

BSE Limited  
The Calcutta Stock Exchange Ltd  
MSE India Limited

### Statutory Auditors:-

M/s. Bipin & Co.,  
Chartered Accountants,  
Vadodara

### Secretarial Auditor:-

M/s. K. H. & Associates, Company  
Secretaries in practice  
Vadodara

## BANKERS:

Central Bank of India      Bank of India

### Registered Office:

CUBICLE NO.:126,3/2,75C,PARK STREET,3RD FLOOR  
KAMDHENU BUILDING, KOLKATA - 700016  
Phone: 033-23988213  
Fax: 033-23968420  
E Mail: [shreeganeshbiotechindia ltd@gmail.com](mailto:shreeganeshbiotechindia ltd@gmail.com)  
Website: [www.shreeganeshbiotech.com](http://www.shreeganeshbiotech.com)

### Registrar & Transfer Agents:

SATELLITE CORPORATE SERVICES PRIVATE LIMITED  
Office No 106-107, Dattani Plaza, East West Compound,  
Andheri Kurla Road, Safedpul  
Sakinaka, Mumbai, Maharashtra, 400072 Phone: 022-  
28520461  
E Mail: [service@satellitecorporate.com](mailto:service@satellitecorporate.com)  
Website: [www.satellitecorporate.com](http://www.satellitecorporate.com)

# TABLE OF CONTENTS

## **CORPORATE OVERVIEW**

Corporate information.....	<b>1</b>
----------------------------	----------

## **STATUTORY REPORTS**

Notice of Annual General Meeting.....	<b>3</b>
Directors' Report.....	<b>11</b>
Secretarial Audit Report.....	<b>18</b>
Report on Corporate Governance.....	<b>24</b>

## **FINANCIAL STATEMENTS**

Independent Auditor's Report.....	<b>34</b>
Balance Sheet.....	<b>45</b>
Profit and Loss Account.....	<b>46</b>
Cash Flow Statement.....	<b>47</b>
Notes to the Financial Statements.....	<b>49</b>

## N O T I C E

**NOTICE** is hereby given that the **15TH ANNUAL GENERAL MEETING** of the Members of **SHREE GANESH BIO-TECH (INDIA) LIMITED** will be held at Registered office of the company CUBICLE NO.:126, 3/2, 75C, PARK STREET, 3RD FLOOR KAMDHENU BUILDING, KOLKATA - 700016 on **Friday ,26<sup>th</sup> September, 2025 at 03:00 P.M.** to transact the following business:

**ORDINARY BUSINESS:**

- 1 To receive, consider and adopt the audited financial statements of the Company for the financial year ended March 31, 2025 and the Reports of the Board of Directors and Independent Auditors thereon;
- 2 To appoint a Director in place of Mr. Aman Patel (DIN: 08483544), who retires by rotation being eligible, offers himself for re-appointment.
- 3 To re-appoint statutory auditors and fix their remuneration and in this regard to consider and if thought to pass, with or without modification(s), the following Resolution as an Ordinary Resolution:

**RESOLVED THAT** subject to the provisions of Sections 139, 142 and any other applicable provisions, if any, of the Companies Act, 2013 ("the Act"), and Companies (Audit and Auditors) Rules 2014, ( including any statutory modification(s) or re-enactment thereof for the time being in force), M/s. Bipin & Co., Chartered Accountants, Vadodara (Firm registration number 101509W) retiring statutory auditor be and are hereby reappointed as the Statutory Auditors of the Company to hold office from the conclusion of this Annual General Meeting to Annual General Meeting held 2030 in and at such remuneration as may be fixed by the Board of Directors of the Company on the recommendation of the Audit Committee.

**RESOLVED FURTHER THAT** the Board of directors of the company (including any Committee thereof) be and is hereby authorized to do all such acts and take all such steps as maybe necessary, proper or expedient to give effect to this resolution.

**SPECIAL BUSINESS:**

4. **Approval for enhancement of borrowing limits of the company under section 180(1)(c) of the Companies Act,2013**

To consider and if thought fit, to pass, with or without modification(s), following resolution as an **Special Resolution**:

**RESOLVED THAT** pursuant to the provisions of Sections 180(1)(c) and other applicable provisions, if any, or re-enactments thereof, for the time being in force read with the of the Companies Act, 2013 (including any statutory modification or the rules made there under, as may be amended from time to time, consent of the members of the Company (hereinafter referred as 'Board' which term shall include a Committee thereof authorized for the purpose) be and are hereby accorded to borrow any sum or sum of money, from time to time from any one or more persons, Bank/s, Firms, bodies corporate, foreign lender/s or Financial institutions from any other source in India or outside India whomsoever on such terms and conditions and with or without security as the Board of Directors may think fit notwithstanding that the monies already borrowed and the monies to be borrowed (apart from temporary loans obtained from Company's bankers in the ordinary course of business) may exceed the paid-up capital, free reserves and securities premium of the company, provided that the total principal amount upto which such monies may be raised or borrowed by the Board of Directors shall not exceed the aggregate of the paid up capital, free reserves and securities premium of the company by more than **`Rs 100.00 Crores (Rupees Hundred Crores only)** at any point of time.

**RESOLVED FURTHER THAT** the Board of directors of the company (including any Committee thereof) be and is hereby authorized to do all such acts and take all such steps as maybe necessary, proper or expedient to give effect to this resolution.

**5. Approval for making investments, give loans, guarantees and security in excess of limits specified under section 186 of the Companies Act, 2013**

To consider and if thought fit, to pass, with or without modification(s), the following resolution as a **Special Resolution**:

**“RESOLVED THAT** pursuant to the provisions of the Section 186 and other applicable provisions, if any, of the Companies Act, 2013, read with the Companies (Meeting of the Board and its Powers) Rules, 2014 including any statutory modification/s or re-enactment/s there of consent of the shareholders of the Company be and is hereby accorded to the Board of Directors of the Company (hereinafter called ‘the Board’ which term shall deemed to include any Committee which Board may have constituted or hereinafter constitute to exercise its powers including the powers conferred by this resolution) to (a) give any loan to any person or other body corporate; (b) give any guarantee or provide security in connection with a loan to any other body corporate or person; and (c) acquire by way of subscription, purchase or otherwise, the securities of any other body corporate from time to time in one or more tranches as the Board of Directors as in their absolute discretion deem beneficial and in the interest of the Company, for an amount not exceeding **Rs. 100 Crores (Rupees One Hundred Crores Only)**, notwithstanding that such investments, outstanding loans given or to be given and guarantees and/or security provided may collectively exceed the limits prescribed under Section 186 of the Companies Act, 2013.

**RESOLVED FURTHER THAT** for the purpose of giving effect to this resolution, the Board of Directors of the Company be and is hereby authorized to take from time to time all decisions and such steps as may be necessary for giving loans, guarantees or providing securities or for making such investments and to execute such documents, deeds, writings, papers and/or agreements as may be required and do all such acts, deeds, matters and things, as it may in its absolute discretion, deem fit; necessary or appropriate.”

Registered Office:  
CUBICLE NO.:126,3/2 ,75C,PARK STREET,3RD  
FLOOR KAMDHENU BUILDING, KOLKATA- 700016  
**Date: 22.05.2025**

**By order of the Board,  
For SHREE GANESH BIO-TECH (INDIA) LIMITED**

**AMAN PATEL  
Chairman  
DIN: 08483544**

**Notes:**

1. A member entitled to attend and vote, is entitled to appoint a proxy to attend and vote instead of himself/ herself and the proxy need not be a member of the company. Proxies in order to be effective must be deposited at the registered office of the company in not less than 48 hours before the time fixed for the meeting. The blank proxy form is enclosed.
2. In compliance with the MCA Circulars and SEBI Circular, Notice of the AGM inter-alia, indicating the process and manner of voting through electronic means along with the Annual Report 2024-25 is being sent only through electronic mode to those Members whose e-mail addresses are registered with the Company / Depositories. Members may note that the Notice and Annual Report 2024-25 will also be available on the Company's website, websites of the Stock Exchanges i.e. BSE Limited and on the website of NSDL.
3. Corporate Members intending to send their authorised representative to attend the Annual General Meeting are requested to send to the Company a duly certified copy of the Board Resolution authorising their representative to attend and vote at the Annual General Meeting.
4. The Register of Members and Share Transfer Register of the Company will remain closed from **19<sup>th</sup> September, 2025 to 26<sup>th</sup> September, 2025** (both days inclusive).
5. Members are requested to send their queries to the Company, if any, on accounts and operations of the Company at least seven days before the meeting so that the same could be suitably answered at the meeting.

6. To facilitate easy and cheap transactions in its shares, the Company has dematerialised its shares. Majority of the shareholders have already availed of this facility and de-materialised their shareholdings. Shareholders who have not yet de-materialised their shareholdings are requested to avail of this facility and de-materialise their shareholdings at the earliest. As per Regulation 40 of SEBI Listing Regulations, as amended, securities of listed companies can be transferred only in dematerialized form with effect from 1st April, 2019, except in case of request received for transmission or transposition of securities. In view of this and to eliminate all risks associated with physical shares and for ease of portfolio management, members holding shares in physical form are requested to consider converting their holdings to dematerialized form. Members can contact the Company or RTA for assistance in this regard.
7. The Explanatory Statement pursuant to Section 102 of the Companies Act, 2013 is annexed hereto.
8. Route map for the venue of the Annual General Meeting is given separately along with attendance slip.
9. The information or details required as per Regulation 36(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 Secretarial Standard – 2 on General Meetings issued by the Institute of Company Secretaries of India, of the person seeking appointment/ re-appointment as a Director at the ensuing Annual General Meeting is as under:

Name of the Director	AMAN PATEL
DIN	08483544
Date of Birth	29/03/1998
Nationality	Indian
Date of Appointment	21/03/2020
Expertise in specific functional Area and experience	Operations and General Management
Terms and Conditions of re-appointment along with details of remuneration sought to be paid	Refer item no. 2 of the Notice
Remuneration last drawn (including sitting fees, if any)	Nil
Directorship in other Companies (excluding Foreign, private and Section 8 companies)	Refer Corporate Governance Report
Membership of Committees in other Public Limited Companies	Refer Corporate Governance Report
No. of Shares held in the Company as on 31.03.2025 (Face Value ₹ 1/- per share)	Nil
Number of meetings of the Board attended during the Financial Year	Refer Corporate Governance Report
Relationship with other Directors, Manager and Key Managerial Personnel of the Company	None
Resignation from Listed Entities in past three years	None

#### THE INSTRUCTIONS FOR MEMBERS FOR REMOTE E-VOTING ARE AS UNDER

The remote e-voting period begins on **Tuesday, 23rd September, 2025 at 09:00 A.M. and ends on Thursday, 25th September, 2025 at 05:00 P.M.** The remote e-voting module shall be disabled by NSDL for voting thereafter. The Members, whose names appear in the Register of Members / Beneficial Owners as on the record date (cut-off date) i.e. **Friday, 19th September 2025**, may cast their vote electronically. The voting right of shareholders shall be in proportion to their share in the paid-up equity share capital of the Company as on the cut-off date, being **Friday, 19th September 2025**

#### How do I vote electronically using NSDL e-Voting system?

The way to vote electronically on NSDL e-Voting system consists of “Two Steps” which are mentioned below:





#### Step 1: Access to NSDL e-Voting system

#### A) Login method for e-Voting for Individual shareholders holding securities in demat mode

In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

Login method for Individual shareholders holding securities in demat mode is given below:

Type of shareholders	Login Method
Individual Shareholders holding securities in demat mode with NSDL.	1. Existing <b>IDeAS</b> user can visit the e-Services website of NSDL Viz. <a href="https://eservices.nsdl.com">https://eservices.nsdl.com</a> either on a Personal Computer or on a mobile. On the e-Services home page click on the “ <b>Beneficial Owner</b> ” icon under “ <b>Login</b> ” which is available under ‘ <b>IDeAS</b> ’ section, this will prompt you to enter your existing User ID and Password. After successful authentication, you will be able to see e-Voting services under Value added services. Click on “ <b>Access to e-Voting</b> ” under e-Voting

	<p>services and you will be able to see e-Voting page. Click on company name or <b>e-Voting service provider i.e. NSDL</b> and you will be re-directed to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting &amp; voting during the meeting.</p> <ol style="list-style-type: none"> <li>If you are not registered for IDeAS e-Services, option to register is available at <a href="https://eservices.nsdl.com">https://eservices.nsdl.com</a>. Select “<b>Register Online for IDeAS Portal</b>” or click at <a href="https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp">https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp</a></li> <li>Visit the e-Voting website of NSDL. Open web browser by typing the following URL: <a href="https://www.evoting.nsdl.com/">https://www.evoting.nsdl.com/</a> either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon “Login” which is available under ‘Shareholder/Member’ section. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or <b>e-Voting service provider i.e. NSDL</b> and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting &amp; voting during the meeting.</li> <li>Shareholders/Members can also download NSDL Mobile App “<b>NSDL Speede</b>” facility by scanning the QR code mentioned below for seamless voting experience. <b>NSDL Mobile App is available on</b></li> </ol> <div style="display: flex; justify-content: space-around; align-items: center;"> <div style="text-align: center;">  <p>App Store</p>  </div> <div style="text-align: center;">  <p>Google Play</p>  </div> </div>
Individual Shareholders holding securities in demat mode with CDSL	<ol style="list-style-type: none"> <li>Users who have opted for CDSL Easi / Easiest facility, can login through their existing user id and password. Option will be made available to reach e-Voting page without any further authentication. The users to login Easi /Easiest are requested to visit CDSL website <a href="http://www.cdslindia.com">www.cdslindia.com</a> and click on login icon &amp; New System Myeasi Tab and then user your existing my easi username &amp; password.</li> <li>After successful login the Easi / Easiest user will be able to see the e-Voting option for eligible companies where the evoting is in progress as per the information provided by company. On clicking the evoting option, the user will be able to see e-Voting page of the e-Voting service provider for casting your vote during the remote e-Voting period or joining virtual meeting &amp; voting during the meeting. Additionally, there is also links provided to access the system of all e-Voting Service Providers, so that the user can visit the e-Voting service providers’ website directly.</li> <li>If the user is not registered for Easi/Easiest, option to register is available at CDSL website <a href="http://www.cdslindia.com">www.cdslindia.com</a> and click on login &amp; New System Myeasi Tab and then click on registration option.</li> <li>Alternatively, the user can directly access e-Voting page by providing Demat Account Number and PAN No. from a e-Voting link available on <a href="http://www.cdslindia.com">www.cdslindia.com</a> home page. The system will authenticate the user by sending OTP on registered Mobile &amp; Email as recorded in the Demat Account. After successful authentication, user will be able to see the e-Voting option where the evoting is in progress and also able to directly access the system of all e-Voting Service Providers.</li> </ol>
Individual Shareholders (holding securities in demat mode) login through their depository participants	<p>You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. upon logging in, you will be able to see e-Voting option. Click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting &amp; voting during the meeting.</p>

**Important note:** Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned website.

**Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. NSDL and CDSL.**

Login type	Helpdesk details
Individual Shareholders holding securities in demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at <a href="mailto:evoting@nsdl.com">evoting@nsdl.com</a> or call at 022 - 4886 7000
Individual Shareholders holding securities in demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at <a href="mailto:helpdesk.evoting@cdslindia.com">helpdesk.evoting@cdslindia.com</a> or contact at toll free no. 1800-21-09911

**B) Login Method for e-Voting for shareholders other than Individual shareholders holding securities in demat mode and shareholders holding securities in physical mode.**

**How to Log-in to NSDL e-Voting website?**

1. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: <https://www.evoting.nsdl.com/> either on a Personal Computer or on a mobile.
2. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section.
3. A new screen will open. You will have to enter your User ID, your Password/OTP and a Verification Code as shown on the screen.  
*Alternatively, if you are registered for NSDL eservices i.e. IDEAS, you can log-in at <https://eservices.nsdl.com/> with your existing IDEAS login. Once you log-in to NSDL eservices after using your log-in credentials, click on e-Voting and you can proceed to Step 2 i.e. Cast your vote electronically.*
4. Your User ID details are given below :

Manner of holding shares i.e. Demat (NSDL or CDSL) or Physical	Your User ID is:
a) For Members who hold shares in demat account with NSDL.	8 Character DP ID followed by 8 Digit Client ID For example if your DP ID is IN300*** and Client ID is 12***** then your user ID is IN300***12*****.
b) For Members who hold shares in demat account with CDSL.	16 Digit Beneficiary ID For example if your Beneficiary ID is 12***** then your user ID is 12*****.
c) For Members holding shares in Physical Form.	EVEN Number followed by Folio Number registered with the company For example if folio number is 001*** and EVEN is 101456 then user ID is 101456001***

5. Password details for shareholders other than Individual shareholders are given below:
  - a) If you are already registered for e-Voting, then you can use your existing password to login and cast your vote.
  - b) If you are using NSDL e-Voting system for the first time, you will need to retrieve the 'initial password' which was communicated to you. Once you retrieve your 'initial password', you need to enter the 'initial password' and the system will force you to change your password.
  - c) How to retrieve your 'initial password'?
    - (i) If your email ID is registered in your demat account or with the company, your 'initial password' is communicated to you on your email ID. Trace the email sent to you from NSDL from your mailbox. Open the email and open the attachment i.e. a .pdf file. Open the .pdf file. The password to open the .pdf file is your 8 digit client ID for NSDL account, last 8 digits of client ID for CDSL account or folio number for shares held in physical form. The .pdf file contains your 'User ID' and your 'initial password'.
    - (ii) If your email ID is not registered, please follow steps mentioned below in process for those shareholders whose email ids are not registered.



6. If you are unable to retrieve or have not received the "Initial password" or have forgotten your password:
  - a) Click on "[Forgot User Details/Password?](#)" (If you are holding shares in your demat account with NSDL or CDSL) option available on [www.evoting.nsdl.com](http://www.evoting.nsdl.com).
  - b) [Physical User Reset Password?](#)" (If you are holding shares in physical mode) option available on [www.evoting.nsdl.com](http://www.evoting.nsdl.com).
  - c) If you are still unable to get the password by aforesaid two options, you can send a request at [evoting@nsdl.com](mailto:evoting@nsdl.com), mentioning your demat account number/folio number, your PAN, your name and your registered address etc.
  - d) Members can also use the OTP (One Time Password) based login for casting the votes on the e-Voting system of NSDL.
7. After entering your password, tick on Agree to "Terms and Conditions" by selecting on the check box.
8. Now, you will have to click on "Login" button.
9. After you click on the "Login" button, Home page of e-Voting will open.

## Step 2: Cast your vote electronically on NSDL e-Voting system.

1. After successful login at Step 1, you will be able to see all the companies "EVEN" in which you are holding shares and whose voting cycle is in active status.
2. Select "EVEN" of company for which you wish to cast your vote during the remote e-Voting period and casting your vote during the General Meeting.
3. Now you are ready for e-Voting as the Voting page opens.
4. Cast your vote by selecting appropriate options i.e. assent or dissent, verify/modify the number of shares for which you wish to cast your vote and click on "Submit" and also "Confirm" when prompted.
5. Upon confirmation, the message "Vote cast successfully" will be displayed.
6. You can also take the printout of the votes cast by you by clicking on the print option on the confirmation page.
7. Once you confirm your vote on the resolution, you will not be allowed to modify your vote.

## General Guidelines for shareholders

1. Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) are required to send scanned copy (PDF/JPG Format) of the relevant Board Resolution/ Authority letter etc. with attested specimen signature of the duly authorized signatory(ies) who are authorized to vote, to the Scrutinizer by e-mail to [dakshanegi@gmail.com](mailto:dakshanegi@gmail.com) with a copy marked to [evoting@nsdl.com](mailto:evoting@nsdl.com). Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) can also upload their Board Resolution / Power of Attorney / Authority Letter etc. by clicking on "Upload Board Resolution / Authority Letter" displayed under "e-Voting" tab in their login.
2. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential. Login to the e-voting website will be disabled upon five unsuccessful attempts to key in the correct password. In such an event, you will need to go through the "[Forgot User Details/Password?](#)" or "[Physical User Reset Password?](#)" option available on [www.evoting.nsdl.com](http://www.evoting.nsdl.com) to reset the password.
3. In case of any queries, you may refer the Frequently Asked Questions (FAQs) for Shareholders and e-voting user manual for Shareholders available at the download section of [www.evoting.nsdl.com](http://www.evoting.nsdl.com) or call on.: 022 - 4886 7000 or send a request to Ms. Pallavi Mhatre at [evoting@nsdl.com](mailto:evoting@nsdl.com).

## Process for those shareholders whose email ids are not registered with the depositories for procuring user id and password and registration of e mail ids for e-voting for the resolutions set out in this notice:

1. In case shares are held in physical mode please provide Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) by email to [shreeganeshbiotechindia@gmail.com](mailto:shreeganeshbiotechindia@gmail.com).
2. In case shares are held in demat mode, please provide DPID-CLID (16 digit DPID + CLID or 16 digit beneficiary ID), Name, client master or copy of Consolidated Account statement, PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) to [shreeganeshbiotechindia@gmail.com](mailto:shreeganeshbiotechindia@gmail.com). If you are an Individual shareholders holding securities in demat mode, you are requested to refer to the login method explained at **step 1 (A) i.e. Login method for e-Voting for Individual shareholders holding securities in demat mode.**
3. Alternatively shareholder/members may send a request to [evoting@nsdl.com](mailto:evoting@nsdl.com) for procuring user id and password for e-voting by providing above mentioned documents.
4. In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are required to update their mobile number and email ID correctly in their demat account in order to access e-Voting facility

**ANNEXURE TO NOTICE  
EXPLANATORY STATEMENT UNDER SECTION 102 OF THE COMPANIES ACT, 2013**

**Item No. 3 Re-appointment of the Statutory Auditor**

M/s. Bipin & Co, Chartered Accountants, Vadodara (Firm registration number 101509W), were appointed as Statutory Auditors of the Company at the 14<sup>th</sup> Annual General Meeting held on 28<sup>th</sup> September 2024 for a term of one year upto the conclusion of this 15<sup>th</sup> Annual General Meeting . M/s. Bipin & Co. are eligible for reappointment as statutory auditors of the company. M/s. Bipin & Co. have given their consent for their reappointment as Statutory Auditors of the Company and has issued certificate confirming that their reappointment, if made, will be within the limits prescribed under the provisions of Section 139 of the Companies Act, 2013 ('the Act') and the rules made thereunder. M/s. Bipin & Co. have confirmed that they are eligible for the proposed appointment under the Act.

The remuneration proposed to be paid to the Statutory Auditors would be in line with the existing remuneration and shall be commensurate with the services to be rendered by them during the said tenure.

The Board of Directors in consultation with the Audit Committee may alter and vary the terms and conditions of appointment, including remuneration, in such manner and to such extent as may be mutually agreed with the Statutory Auditors.

None of the Directors and Key Managerial Personnel of the Company and their relatives, are in any way concerned or interested in this Resolution.

The Board recommends this Ordinary Resolution for the approval of shareholders.

**Item No. 4 Approval for enhancement of borrowing limits of the company under section 180(1)(c) of the Companies Act, 2013**

As per the provisions of Section 180 (1) (c) of the Companies Act, 2013, the Board of Directors of the Company cannot, except with the permission of the Shareholders in General Meeting by passing a Special Resolution, borrow monies in excess of the aggregate of the paid-up share capital, free reserves and securities premium apart from temporary loans obtained from the company's bankers in the ordinary course of business only with the consent of the company by a special resolution. of the Company.

Taking into consideration the growth in the business operations, foreseeable future plans and the existing credit facilities availed by the Company, it would be in the interest of the Company to enhance the borrowing limit. Keeping in view the existing and future financial requirements to support the business operations of the Company, it is proposed to increase the maximum borrowing limit up to Rs 100.00 Crores (Rupees Hundred Crores only). For the said proposal the shareholders' approval u/s 180(1)(c) is required.

None of the Directors, Key Managerial Personnel of the Company or their relatives is, in any way, concerned or interested in the resolution, except to the extent of their equity holding in the Company.

The Board of Directors of recommends the Special Resolution for approval of the Shareholders.

**Item No.5 Approval for making investments, give loans, guarantees and security in excess of limits specified under section 186 of the Companies Act, 2013**

As per Section 186 of the Companies Act, 2013, a Company can invest/provide loans/ give guarantees upto 60% of its paid up share capital, free reserves and securities premium account or 100% of its free reserves and securities premium account, whichever is higher.

Consequently, it is proposed to authorise the Board of Directors of the Company to give any guarantee(s) and/ or provide any security(ies) in connection with loan(s) made upto Rs 100.00 Crores (Rupees Hundred Crores only). to any other body corporate.

None of the Directors, Managers and Key Managerial Personnel of the Company or their respective relatives is concerned or interested in the Resolution.

The Board of Directors of recommends the Special Resolution for approval of the Shareholders.

Registered Office:  
CUBICLE NO.:126,3/2 ,75C,PARK STREET,3RD  
FLOOR KAMDHENU BUILDING, KOLKATA- 700016  
**Date: 22.05.2025**

By order of the Board,  
For SHREE GANESH BIO-TECH (INDIA) LIMITED

**AMAN PATEL**  
Chairman  
DIN: 08483544

## Directors' Report to the Members

Your Directors have pleasure in presenting their 15<sup>th</sup> Annual Report on the business and operations of the Company together with the Audited Accounts of the Company for the financial year ended March 31, 2024.

### **FINANCIAL SUMMARY**

Summary of the Company's financial performance for F.Y. 2024-25 as compared to the previous financial year is given below:

	Amount in Rs.	Amount in Rs.
<b>Particulars</b>	<b>31.03.2025</b>	<b>31.03.2024</b>
Net Sales /Income from Business Operations	229575557	202777150
Other Income	14409349	10562920
<b>Total Income</b>	<b>243984906</b>	<b>213340070</b>
Less Interest	60	510
Profit before Depreciation	3869147	8549346
Less Depreciation	5320	5320
<b>Profit after depreciation and Interest</b>	<b>3874467</b>	<b>8554666</b>
Less Current Income Tax	1085143	2342167
Less Previous year adjustment of Income Tax	0	0
Less Deferred Tax	0	0
<b>Net Profit after Tax</b>	<b>2784004</b>	<b>6207179</b>
Earning per share (Basic)	<b>0.01</b>	<b>0.02</b>
Earning per Share (Diluted)	<b>0.01</b>	<b>0.02</b>

### **STATE OF COMPANY'S AFFAIR**

The Company is engaged in the business of production, processing and marketing of high-quality hybrid seeds for different crops like corn, sunflower, cotton, paddy, grain sorghum, etc., and 100% of the total revenue of the Company is derived from these activities.

### **DIVIDEND**

In order to consolidate the Company's financial position, your directors consider it prudent not to recommend dividend for the year under review.

### **DEPOSITS**

The Company has not accepted any deposits within the meaning of Section 73 of the Companies Act, 2013 and the Companies (Acceptance of Deposits) Rules, 2014. As such, no amount on account of principal or interest on public deposits was outstanding as on the date of the balance sheet.

### **AMOUNTS TO BE TRANSFERRED TO RESERVES**

No amount is proposed to carry to any reserves by the board of directors.

### **SHARE CAPITAL**

The authorized share capital of the Company is Rs. 40,00,00,000/- divided into 40,00,00,000 Equity Shares of Rs. 1/- each. The paid up share capital of the company are Rs. 39,86,24,000/- divided into 398624000 Equity shares of Rs. 1/- each.

### **SUBSIDIARIES, JOINT VENTURES OR ASSOCIATE COMPANIES**

The Company does not have any subsidiary, associate companies & joint ventures.

### **CHANGES IN THE NATURE OF BUSINESS**

During the year under review, there has been no change in the nature of business of the Company.

### **MATERIAL CHANGES AND COMMITMENTS IF ANY AFFECTING THE FINANCIAL POSITION OF THE COMPANY**

No material changes and commitments affecting the financial position of the company have occurred between the end of financial year to which the financial statements relate and the date of the Directors' Report.

**SIGNIFICANT ORDERS PASSED BY THE REGULATORS, COURTS OR TRIBUNALS IMPACTING GOING CONCERN AND COMPANY'S OPERATIONS**

To the best of our knowledge, the company has not received any such orders passed by the regulators, courts or tribunals during the year, which may impact the going concern status or company's operations in future.

**INTERNAL CONTROL SYSTEMS**

The Company has an adequate Internal Control System, commensurate with the size, scale and complexity of its operations. To maintain its objectivity and independence, the Internal Audit function reports to the Chairman of the Audit Committee of the Board & to the Chairman & Managing Director.

The Internal Audit Department monitors and evaluates the efficacy and adequacy of internal control system in the Company, its compliance with operating systems, accounting procedures and policies of the Company. Based on the report of internal audit, management undertakes corrective action in their respective areas and thereby strengthens the controls. Significant audit observations and corrective actions thereon are presented to the Audit Committee of the Board.

**PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS**

There were no loans, guarantees or investments made by the Company under Section 186 of the Companies Act, 2013 during the year under review and hence the said provision is not applicable.

**PARTICULARS OF CONTRACTS OR ARRANGEMENTS WITH RELATED PARTIES U/S 188(1)**

During the year under review, the Company has not entered into any contract or arrangement falling under ambit of Section 188 of the Companies Act, 2013. Hence, disclosure of particulars of contract or arrangement with related parties in Form AOC-2 is not applicable to the Company.

**DIRECTORS AND KEY MANAGERIAL PERSONNEL**

The Board of Directors consists of 6 members, out of which 4 are Independent Directors including women Independent Director and 2 are Executive Directors. The composition is in compliance with the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

As per the provisions of Section 152(6) of the Companies Act, 2013 Mr. Aman Patel (DIN: 08483544) shall retire by rotation at the ensuing Annual General Meeting and being eligible, has offered himself for re-appointment as the Director of the Company.

As per the provisions of Section 203 of the Companies Act, 2013, Mr. Aman Pravinkumar Patel is Whole Time Director, Mr. Kishan Nityanand Naidu is Chief Financial Officer and Ms. Namita Acharya Company Secretary is the key managerial personnel of the Company.

**DECLARATION BY INDEPENDENT DIRECTORS:**

The Company has received necessary declaration from each Independent Director under Section 149 (7) of the Companies Act, 2013, that they meet the criteria of independence laid down in Section 149(6) of the Companies Act, 2013.

**SIGNIFICANT ORDERS PASSED BY THE REGULATORS, COURTS OR TRIBUNALS IMPACTING GOING CONCERN AND COMPANY'S OPERATIONS:**

To the best of our knowledge, the company has not received any such orders passed by the regulators, courts or tribunals during the year, which may impact the going concern status or company's operations in future.

**PECUNIARY RELATIONSHIP OR TRANSACTIONS OF NON-EXECUTIVE DIRECTORS**

During the year, the Non-Executive Directors of the Company had no pecuniary relationship or transactions with the Company.

**BOARD EVALUATION**

Pursuant to the provisions of the Companies Act, 2013, Regulation 17(10) of the Listing Regulations and in line with our corporate governance guidelines, peer evaluation of all Board members, annual performance evaluation of its own performance, as well as the evaluation of the working of Board's Committees was undertaken. This evaluation is led by the Chairman of the Nomination and Remuneration Committee with specific focus on the performance and effective functioning of the Board and its Committees. The evaluation process also considers the time spent by each of the Board members, core competencies, personal characteristics, accomplishment of specific responsibilities and expertise.

The performance of the Board was evaluated by the Board after seeking inputs from all the Directors on the basis of the criteria such as the Board composition and structure, effectiveness of board processes, information and functioning, etc.

The performance of the Committees was evaluated by the Board after seeking inputs from the Committee Members on the basis of the criteria such as the composition of Committees, effectiveness of Committee meetings, etc.

**CODE OF CONDUCT**

The Directors and members of Senior Management have affirmed compliance with the Code of Conduct for Directors and Senior Management of the Company. A declaration to this effect has been signed by Managing Directors and forms part of the Annual Report.

**NUMBER OF MEETINGS OF THE BOARD**

The details of the number of meetings of the Board held during the Financial Year 2024-25 forms part of the Corporate Governance Report.

**COMMITTEES OF THE BOARD**

The Board of Directors has the following Committees:

1. Audit Committee
2. Nomination and Remuneration Committee
3. Stakeholders' Relationship Committee

The details of the Committees along with their composition, number of meetings and attendance at the meetings are provided in the Corporate Governance Report.

**VIGIL MECHANISM**

The Company has adopted a vigil mechanism named Whistle Blower Policy for directors and employees to report genuine concerns which shall provide adequate safeguards against victimization of persons who use such mechanism. Under this policy, we encourage our employees to report any reporting of fraudulent financial or other information to the stakeholders, any conduct that results in violation of the Company's Code of Business Conduct, to management (on an anonymous basis, if employees so desire).

Likewise, under this policy, we have prohibited discrimination, retaliation or harassment of any kind against any employees who, based on the employee's reasonable belief that such conduct or practice have occurred or are occurring, reports that information or participates in the said investigation.

This meets the requirement under Section 177(9) and (10) of the Companies Act, 2013 and Regulation 22 of the Listing Regulations.

No individual in the Company has been denied access to the Audit Committee or its Chairman.

**MANAGERIAL REMUNERATION AND PARTICULARS OF EMPLOYEES**

The particulars of Managerial remuneration as stated in Section 134(3)(q) of the Companies Act, 2013 read with rules 5(1) of the Companies (Appointment and Remuneration of Managerial personnel) Rules, 2014, is annexed herewith and forms part of this Board's Report.

None of the employees was engaged in the company, who were in receipt of remuneration in excess of the limits as specified under Rule 5(2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, throughout or part of the financial year under review.

**EXTRACT OF ANNUAL RETURN**

Pursuant to Section 92(3) read with Section 134(3) (a) of the Companies Act 2013, the Annual Return as on 31st March 2025 is available on the website of the Company at [www.shreeganeshbiotech.com](http://www.shreeganeshbiotech.com).

**AUDITORS AND AUDITORS' REPORT:**

M/s. Bipin & Co., Chartered Accountants, Vadodara (FRN 101509W), Statutory Auditors of the Company to hold office from the conclusion this AGM until the conclusion of the AGM to be held in the year of 2030, for period of 5 years.

The observations made by the Auditors' in their Auditors' Report and the Notes on Accounts referred to in the Auditors' Report are self-explanatory and do not call for any further comments.

**SECRETARIAL AUDITOR & SECRETARIAL AUDIT REPORT**

Pursuant to provisions of section 204 of the Companies Act, 2013 and The Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 the Company has appointed M/s. Daksha Negi & Associates, Company Secretaries in practice to undertake the Secretarial Audit of the Company. The Secretarial Audit report in the prescribed Form No MR-3 is annexed herewith.

**QUALIFICATION IN SECRETARIAL AUDIT REPORT AND EXPLANATIONS BY THE BOARD:**

Sr. No.	Qualifications made by Secretarial Auditor	Explanations by the Board
a)	The company has not complied with certain regulation of SEBI (LODR) Regulations, 2015 as regards publication of Notice of Board Meeting, Notice of AGM, quarterly results.	The company will take necessary steps to comply with the same.
b)	As per section 138 of the Companies Act, 2013, the Company is required to appoint Internal Auditor. The Company has not appointed Internal Auditor.	The size of operation of the Company is very small, it is not viable to appoint Internal Auditor but the Company has established the internal control system.

**CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNING & OUTGO**

The details of conservation of energy, technology absorption etc. as required to be given under Section 134(3)(m) of the Companies Act, 2013 read with Rule, 8 of The Companies (Accounts) Rules, 2014, are not applicable to Company, as our Company has not carried out in the manufacturing activities.

The foreign exchange earning on account of the operation of the Company during the year was Rs. Nil.

**REPORT ON CORPORATE GOVERNANCE & MANAGEMENT DISCUSSION & ANALYSIS**

Pursuant to Regulation 34(3) read with Schedule V of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Company has taken adequate steps to ensure that all mandatory provisions of Corporate Governance as prescribed under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are complied with, a separate section titled Report on Corporate Governance together with a Certificate from the Practicing Company Secretary forms part of this Report. A detailed Management Discussion & Analysis forms part of this Report.

**CORPORATE SOCIAL RESPONSIBILITY**

In terms of the provisions of Section 135 of the Companies Act, 2013 read together with relevant Rules, the "Corporate Social Responsibility" (CSR) requirement is not applicable to the Company.

**DISCLOSURE UNDER PREVENTION OF SEXUAL HARASSMENT OF WOMEN AT WORKPLACE ("POSH") (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013**

The Company has zero tolerance for sexual harassment at workplace and has adopted a policy on prevention, prohibition and redressal of sexual harassment at workplace in line with the provisions of Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 and the rules framed thereunder. During the financial year 2024-25, no complain had been received.

**DISCLOSURE UNDER SECTION 197(12) OF THE COMPANIES ACT, 2013 AND OTHER DISCLOSURES AS PER RULE 5 OF COMPANIES (APPOINTMENT & REMUNERATION) RULES, 2014:**

Pursuant to Section 197(12) of the Companies Act, 2013 and Rule 5 of Companies (Appointment & Remuneration) Rules, 2014 every Listed Company mandates to disclose in the Board's Report the ratio of the remuneration of each director to the permanent employee's remuneration. However, since there is no permanent employee in the Company, no disclosure under the said provision has been furnished.



**RISK MANAGEMENT POLICY**

The Company has in place a Business Risk Management Framework. The risk management framework commensurate with the size of the Company's operation and provides for, inter alia, identification of elements of risk, pro-active approach for its minimization and mitigation.

The Board has been regularly informed about risk assessment and minimization procedures. The main objective of this policy is to ensure sustainable business growth with stability.

**DIRECTORS' RESPONSIBILITY STATEMENT:**

The Directors' Responsibility Statement referred to in clause (c) of sub-section (3) of Section 134 of the Companies Act, 2013, shall state that:

- a) In the preparation of the annual accounts, the applicable accounting standards have been followed along with proper explanation by way of notes to accounts relating to material departures;
- b) the Directors have selected such accounting policies and applied them consistently and made judgments and estimates that were reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profit or loss of the Company for that period;
- c) the Directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013 for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;
- d) Directors have prepared the accounts on a "going concern basis".
- e) the directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

**HUMAN RESOURCES & INDUSTRIAL RELATIONS**

The Company has always provided a congenial atmosphere for work to all sections of society. It has provided equal opportunities of employment to all irrespective to their caste, religion, color, marital status and sex. The Company believes that human capital of the Company is its most valuable assets and its human resource policies are aligned towards this objective of the Company.

The relation amongst its employees remained harmonious and the year under review remained free from any labor unrest.

**GENERAL:**

The Board of Directors state that no disclosure or reporting is required in respect of the following matters as there were no transactions or applicability pertaining to these matters during the year under review:

- i) Fraud reported by the Auditors to the Audit Committee or the Board of Directors of the Company.
- ii) Payment of remuneration or commission from any of its subsidiary companies to the Managing Director/ Whole Time Director of the Company.
- iii) Voting rights which are not directly exercised by the employees in respect of shares for the subscription/ purchase of which loan was given by the Company (as there is no scheme pursuant to which such persons can beneficially hold shares as envisaged under section 67(3)(c) of the Companies Act, 2013).
- iv) Details of any application filed for corporate insolvency under Corporate Insolvency Resolution Process under the Insolvency and Bankruptcy Code, 2016.
- v) One time settlement of loan obtained from the banks or financial institutions.

**MATERNITY BENEFIT( Rule 8(5)(xiii) of Companies (Account) Rules, 2014)**

The Company affirms that it has duly complied with all provisions of the Maternity Benefit Act, 1961, and has extended all statutory benefits to eligible women employees during the year 2024-25.

**ACKNOWLEDGEMENTS:**

Your Directors take this opportunity to thank the Regulatory and Government Authorities, Bankers, Business Associates, Shareholders and the Customers of the Company for their continued support to the Company. The Directors express their deep sense of appreciation towards all the employees and staff of the Company and wish the management all the best for achieving greater heights in the future.



**SHREE GANESH BIO-TECH (INDIA) LIMITED**

**For and on Behalf of the Board  
For, SHREE GANESH BIO-TECH (INDIA) LIMITED**

**Place: Kolkata  
Date: 22.05.2025**

**KISHAN NAIDU  
Director  
DIN: 08662664**

**AMAN PATEL  
Wholetime Director  
DIN: 08483544**

**Annexure to Director's Report****PARTICULARS OF EMPLOYEES PURSUANT TO SECTION 134(3)(q) OF THE COMPANIES ACT, 2013 READ WITH RULES 5(1) OF THE COMPANIES (APPOINTMENT AND REMUNERATION OF MANAGERIAL PERSONNELS) RULES, 2014**

**Particulars of Managerial remuneration as stated in section 197 of the Companies Act, 2013 read with Rules 5(1) of the Companies (Appointment and Remuneration of Managerial personnel) Rules, 2014**

**I. Ratio of Remuneration of each director to the median remuneration of the employees of the company for the financial year**

No remuneration has been paid to any of the Directors of the Company during the year under review, and that remuneration is paid only to the Company Secretary of the Company during the financial year. Accordingly, ratio is not ascertainable.

**II. The percentage increase in the remuneration of each Director, Chief Financial Officer, Chief Executive Officer, Company Secretary or Manager, if any, in the financial year.**

The Company has employed only Company Secretary during the financial year under review. However, there is only increase in her remuneration during the year under review.

**III. The percentage increase in the median remuneration of the employees in the financial year**

There is no increase in remuneration of any of the employees of the Company during the year under review.

**IV. The number of permanent employees on the rolls of the company**

As on March 31, 2025, the Company have Five (5) employees on the roll of the Company.

**V. The explanation on the relationship between average increase in remuneration and company performance**

Not applicable - No remuneration has been paid to any of the Directors of the Company during the year under review and that there has been no increase in remuneration of any of the employees.

**VI. Comparison of the remuneration of the Key Managerial Personnel against the performance of the company**

The Company has only one Key Managerial Personnel (KMP), i.e. Company Secretary. During the year under review, the remuneration increased by 7.20 % and paid to her is **Rs.1,74,000**

**VII. Average percentile increase already made in the salaries of employees other than the managerial personnel in the last financial year and its comparison with the percentile increase in the managerial remuneration and justification thereof.**

The Company has only one Key Managerial Personnel (KMP), i.e. Company Secretary, and no other employees during the financial year. Further, there is 7.20 % increase in the salary of the Company Secretary. Therefore, the average percentile increase already made in the salaries of employees other than the managerial personnel in the last financial year and its comparison with the percentile increase in the managerial remuneration is not ascertainable.

**VIII. The key parameters for any variable component of remuneration availed by the directors.**

No remuneration is paid to any of the Directors of the Company during the year under review.

**IX. The ratio of the remuneration of the highest paid director to that of the employees who are not directors but receive remuneration in excess of the highest paid director during the year.**

No remuneration is paid to any of the Directors of the Company during the year under review. Hence, the same is not ascertainable.

**X. Affirmation that the remuneration is as per the remuneration policy of the company.**

At present, no remuneration has been paid to any of the Directors of the Company during the year under review. However, the Board of Directors hereby affirms that the remuneration, if any paid in future, to any of the directors, KMPs shall be in accordance with the Nomination and Remuneration Policy of the Company.

**For and on Behalf of the Board  
For, SHREE GANESH BIO-TECH (INDIA) LIMITED**

**Place: Kolkata  
Date: 22.05.2025**

**AMAN PATEL  
Wholetime Director  
DIN: 08483544**

Annexure to Director's Report

Form No. MR-3

**SECRETARIAL AUDIT REPORT FOR THE FINANCIAL YEAR ENDED 31ST MARCH, 2025**

(Pursuant to Section 204(1) of the Companies Act, 2013 and Rule No.9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014)

To,

The Members

**SHREE GANESH BIO-TECH (INDIA) LIMITED**

CIN: L70101WB1982PLC121196

Kolkata

We have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by **M/s. SHREE GANESH BIO-TECH (INDIA) LIMITED** (hereinafter called the company). Secretarial Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing our opinion thereon.

Based on our verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, We hereby report that in our opinion, the Company has, during the audit period covering the financial year ended on **March 31, 2025** complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

We have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the financial year ended on **March 31, 2025** according to the provisions of:

- i) The Companies Act, 2013 and the rules made thereunder;
- ii) The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the rules made there under;
- iii) The Depositories Act, 1996 and the Regulations and Bye-law framed hereunder;
- iv) Foreign Exchange Management Act, 1999 and the Rules and Regulations made there under to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings;
- v) The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'):-
  - a) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
  - b) The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
  - c) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009 - Not applicable as the Company has not issued any shares during the year under review;
  - d) The Securities and Exchange Board of India (Employee Stock Option Scheme and Employee Stock Purchase Scheme) Guidelines, 1999 / Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014 - Not applicable as the Company has not issued any shares/options to directors/employees under the said guidelines / regulations during the year under review;
  - e) The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008 - Not applicable as the Company has not issued any debt securities which were listed during the year under review;
  - f) The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client; - Not applicable as the Company is not registered as Registrar to Issue and Share Transfer Agent during the year under review;

- g) The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009 – Not applicable as the Company has not delisted / propose to delist its equity shares from any Stock Exchange during the year under review; and
- h) The Securities and Exchange Board of India (Buyback of Securities) Regulations, 1998 – No applicable as the Company has not bought back or propose to buy-back any of its securities during the year under review.
- vi) Based on representation made by the Company and its officers, the Company has adequate system and process in place for compliance under the other applicable Laws, Acts, Rules, Regulations, Circulars, Guidelines and Standards.
- vii) We have also examined compliance with the applicable clauses of the following:
  - (i) Secretarial Standards with respect to Meetings of Board of Directors (SS-1) and General Meetings (SS-2) issued by The Institute of Company Secretaries of India.
  - (ii) The SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

During the period under review and as per the explanations and clarifications given to us and the representations made by the Management, the Company has generally complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc. mentioned above subject to the following qualifications:

- a) The company has not complied with certain regulation of SEBI (LODR) Regulations, 2015 as regards publication of Notice of Board Meeting, Notice of AGM, quarterly results.**
- b) As per section 138 of the Companies Act, 2013, the Company is required to appoint Internal Auditor. The Company has not appointed Internal Auditor.**

We further report that the compliance by the Company of applicable financial laws, like direct and indirect tax laws, has not been reviewed in this Audit since the same have been subject to review by statutory financial audit and other designated professionals.

We further report that The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.

As per the information received from the company Adequate notice is given to all the directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent at least seven days in advance and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting. Majority decision is carried through while the dissenting members' views are captured and recorded as part of the minutes.

We further report that there are adequate systems and processes in the company commensurate with the size and operations of the company to monitor and ensure compliance with applicable Laws, Rules, Regulations and guidelines.

We further report that during the audit period the Company has not passed any Special / Ordinary Resolutions which are having major bearing on the Company's affairs in pursuance of the above referred laws, rules, regulations, guidelines, standards etc.

We further report that during the audit period, there were no instances of Public/Rights/Preferential issue of Shares/debentures/ sweat equity, Redemption/buy-back of securities, Merger/ amalgamation/ reconstruction etc., Foreign technical collaborations.

**For, Daksha Negi & Associates  
COMPANY SECRETARIES**

**Place : Ahmadabad  
Date : 20.08.2025**

**[CS DAKSHA NEGI]  
Practicing Company Secretary  
ACS No: A41607  
C. P. NO.: 20353  
UDIN: A041607G001041683**

Note: This report is to be read with our letter of even date which is annexed as **Annexure-A** and forms an integral part of this report.

**ANNEXURE - A to Form No MR-3**

To,  
The Members  
**SHREE GANESH BIO-TECH (INDIA) LIMITED**  
CIN: L70101WB1982PLC121196  
Kolkata

Our report of even date is to be read along with this letter.

1. Maintenance of secretarial records is the responsibility of management of the company. Our responsibility is to express an opinion on these secretarial records based on our audit.
2. We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices, we followed provide a reasonable basis for our opinion.
3. We have not verified the correctness and appropriateness of financial records and books of accounts of the company.
4. Wherever required, we have obtained the Management Representation about the compliance of laws, rules and regulations and happening of events, etc.
5. The compliance of the provisions of corporate and other applicable laws, rules and regulations, standards is the responsibility of the management. Our examination was limited to the verification of procedures on test basis.
6. The Secretarial Audit Report is neither an assurance as to the future viability of the company nor of the efficacy or effectiveness with which the management has conducted the affairs of the company.

**For, Daksha Negi & Associates  
COMPANY SECRETARIES**

**Place : Ahmadabad  
Date : 20.08.2025**

**[CS DAKSHA NEGI]  
Practicing Company Secretary  
ACS No: A41607  
C. P. NO.: 20353  
UDIN: A041607G001041683**

*Annexure to Director's Report***MANAGEMENT DISCUSSION ANALYSIS REPORT**

1. **INDUSTRY STRUCTURE AND DEVELOPMENTS:**  
As of now the Company is not engaged in any activity and the management is looking for a right opportunity to make the Company operational.
2. **OVERALL REVIEW:**  
Due to scarcity of working capital funds, the Company is not able to perform any business activities. To make the Company operational, the board is making its best effort to implement the cost reduction measures to the extent feasible. Several cost cutting measures have already been undertaken by the Company.
3. **RISK AND CONCERNS:**  
The Company's future development would depend upon the commencement of its operational activities
4. **INTERNAL CONTROLS SYSTEMS AND THEIR ADEQUACY:**  
The Company is following a proper and adequate system of internal controls in respect of all its activities. Further all transaction entered into by the Company are fully authorised, recorded and reported correctly
5. **FINANCIAL PERFORMANCE WITH RESPECT TO OPERATIONAL PERFORMANCE:**  
During the year under review, the Company did not carry out any activity.
6. **CAUTIONARY STATEMENT:**  
Statements in this Management Discussion and Analysis describing the company's objectives, projections, estimates and expectations may be forward looking statement within the meaning of applicable laws and regulations. Actual results might differ materially from those either expressed or implied.

**For and on Behalf of the Board**  
**For, SHREE GANESH BIO-TECH (INDIA) LIMITED**

**Place: Kolkata**  
**Date: 22.05.2025**

**AMAN PATEL**  
**Wholetime Director**  
**DIN: 08483544**



**Annexure to Director's Report****REPORT ON CORPORATE GOVERNANCE****COMPANY'S PHILOSOPHY ON CODE OF CORPORATE GOVERNANCE:**

Your Company is committed to good Corporate Governance. The Company fully understands the rights of its shareholders to information on the performance of the company and considers itself a trustee of its shareholders. Corporate Governance strengthens investor's trust and ensures a long-term partnership that helps in fulfilling our quest for achieving significant growth and profits.

**BOARD OF DIRECTORS:**

The Board of Directors is consisting of Six Directors. The Directors manages the day to day affairs of the Company. Non-executive and independent directors did not have any pecuniary relationship of transactions with the company during the period under review. There are no material transactions where they have had personal interests that conflict with that of the Company.

The composition of the Board of Directors as on date of this report:

Sr. No.	Name of Director	Executive/ Non—Executive/ Independent	No. of Directorships Held in Public Limited Companies (Including the Company)	#Committee(s) position (Including the Company)	
				Member	Chairman
1	AMAN PATEL	Whole- time(Executive) Director	3	0	0
2	KISHAN NAIDU	CFO (Executive Director)	1	0	0
3	SOMBIR SINGH	Non-Executive Independent	1	1	1
4	AMRUTABEN SOLANKI	Non-Executive Independent	1	1	1
5	NIMESHKUMAR PARMAR	Non-Executive Independent	1	0	0
6	HARSHADKUMAR RATHOD	Non-Executive Independent	3	0	0

# Only Audit Committee and Stakeholders' Relationship Committee has been considered as per Regulation 26 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

**Name of other listed entities where Directors of the company are Directors and the category of Directorship as on date of this report:**

Sr. No.	Name of Director	Name of listed entities in which the concerned Director is a Director	Category of directorship
1	AMAN PATEL	REGIS INDUSTRIES LIMITED	Independent Director
		BIOGEN PHARMACHEM INDUSTRIES LIMITED	Independent Director
2	KISHAN NAIDU	-	-
3	SOMBIR SINGH	-	-
4	AMRUTABEN SOLANKI	-	-
5	NIMESHKUMAR PARMAR	-	-
6	HARSHAD RATHOD	BIOGEN PHARMACHEM INDUSTRIES LIMITED	Independent Director
		SUNCARE TRADERS LIMITED	Whole-time Director and CFO

None of the Directors hold Directorships in more than 20 companies. Further, any individual director's directorships in public companies do not exceed 10. None of the Directors is serving as a member of more than ten committees or as the Chairman of more than five committees across all the public companies of which he is a Director.

**NUMBERS OF BOARD MEETINGS HELD AND THE DATES ON WHICH SUCH MEETINGS WERE HELD:**

During the financial year 2024-25 the Board met 4 (Four) times:-

30<sup>th</sup> May 2024      |      13<sup>th</sup> August 2024      |      23<sup>rd</sup> October 2024      |      04<sup>th</sup> February 2025

Attendance record of Directors attending the Board meetings and Annual General Meetings: -

Name of the Director	Category	No. of Board Meetings Attended	Last AGM attendance
AMAN PATEL	Whole-time Director	4/4	Yes
KISHAN NAIDU	Executive Director	4/4	Yes
SOMBIR SINGH	Non-Executive Independent Director	4/4	Yes
AMRUTABEN SOLANKI	Non-Executive Independent Director	4/4	Yes
NIMESHKUMAR PARMAR	Non-Executive Independent Director	4/4	Yes
HARSHADKUMAR RATHOD	Non-Executive Independent Director	4/4	Yes

#### MEETING OF INDEPENDENT DIRECTORS:

The Company's Independent Directors met on 04<sup>th</sup> February 2025 without the presence of the Executive Director and the Senior Management team. The meeting was attended by majority of Independent Directors and was conducted to enable the Independent Director to discuss matters prescribed under Schedule IV to the Act and Regulation 25(3) of the SEBI (LODR) Regulation, 2015.

**The Board has identified the following skills/expertise/competencies with reference to its business for the effective functioning of the Company and which are currently available with the Board:**

Following capabilities and expertise have been identified by the Board of Directors for it to function effectively, and are available among the board members collectively:

1. Project management – both for ensuring timely delivery of each equipment, as well as for expansion of facilities
2. B2B sales, marketing and account management
3. International business experience covering operations in new geographies
4. Manufacturing and supply chain management including running production facilities
5. Talent management – especially related to engineering skills

In addition, the team would require general management and financial management skills including commercial, legal and regulatory, risk management, industrial relations, and overall stakeholder management. In the table below, the specific areas of focus or expertise of individual Board members have been highlighted. However, the absence of a mark against a member's name does not necessarily mean the member does not possess the corresponding skills/expertise/competencies.

Director	Skill – 1	Skill – 2	Skill – 3	Skill – 4	Skill – 5
SOMBIR SINGH Independent Director	√	√	--	--	√
AMAN PATEL Whole-time Director	√	√	√	√	√
AMRUTABEN SOLANKI Independent Director	√	√	--	--	√
KISHAN NAIDU No-Executive Director	√	√	√	√	√
NIMESHKUMAR PARMAR Independent Director	√	√	--	--	√
HARSHADKUMAR RATHOD Independent Director	√	√	--	--	√

**Disclosure of relationships between the Directors inter-se:** There is no relationship between the Directors inter-se.

#### Number of shares and convertible instruments held by Non-Executive Directors:

Name of Director	No. of Equity Shares held
SOMBIR SINGH	Nil
AMRUTABEN RAJANBHAI SOLANKI	Nil
KISHAN NAIDU	Nil
NIMESHKUMAR MOHANBHAI PARMAR	Nil
HARSHADKUMAR RATHOD	Nil

During the year under review, none of the Non-Executive Directors hold any convertible instruments of the Company.

**AUDIT COMMITTEE:**

The Audit Committee of the Company presently comprises of three members being MR. SOMBIR SINGH, MS. AMRUTABEN SOLANKI and MS. NIMESHKUMAR MOHANBHAI PARMAR.

**Terms of Reference:**

Pursuant to the SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2018, the Company has revised the terms of reference of the Committee. The revised terms of reference are:

- (1) oversight of the company's financial reporting process and the disclosure of its financial information to ensure that the financial statement is correct, sufficient and credible;
- (2) recommendation for appointment, remuneration and terms of appointment of auditors of the company;
- (3) approval of payment to statutory auditors for any other services rendered by the statutory auditors;
- (4) reviewing, with the management, the annual financial statements and auditor's report thereon before submission to the board for approval, with particular reference to:
  - (a) matters required to be included in the director's responsibility statement to be included in the Board's report in terms of clause (c) of sub-section (3) of Section 134 of the Act;
  - (b) changes, if any, in accounting policies and practices and reasons for the same;
  - (c) major accounting entries involving estimates based on the exercise of judgment by management;
  - (d) significant adjustments made in the financial statements arising out of audit findings;
  - (e) compliance with listing and other legal requirements relating to financial statements;
  - (f) disclosure of any related party transactions;
  - (g) modified opinion / Qualification in the draft audit report.
- (5) reviewing, with the management, the quarterly financial statements before submission to the board for approval;
- (6) reviewing, with the management, the statement of uses / application of funds raised through an issue (public issue, rights issue, preferential issue, etc.), the statement of funds utilized for purposes other than those stated in the offer document / prospectus / notice and the report submitted by the monitoring agency monitoring the utilisation of proceeds of a public or rights issue and making appropriate recommendations to the board to take up steps in this matter;
- (7) reviewing and monitoring the auditor's independence, performance and effectiveness of audit process;
- (8) Formulating a policy on related party transactions, which shall include materiality of related party transactions;
- (9) approval or any subsequent modification of transactions of the listed entity with related parties;
- (10) scrutiny of inter-corporate loans and investments;
- (11) valuation of undertakings or assets of the company, wherever it is necessary;
- (12) evaluation of internal financial controls and risk management systems;
- (13) reviewing, with the management, performance of statutory and internal auditors, adequacy of the internal control systems;
- (14) reviewing the adequacy of internal audit function, if any, including the structure of the internal audit department, staffing and seniority of the official heading the department, reporting structure coverage and frequency of internal audit;
- (15) discussion with internal auditors of any significant findings and follow up there on;
- (16) reviewing the findings of any internal investigations by the internal auditors into matters where there is suspected fraud or irregularity or a failure of internal control systems of a material nature and reporting the matter to the board;
- (17) discussion with statutory auditors before the audit commences, about the nature and scope of audit as well as post-audit discussion to ascertain any area of concern;
- (18) to look into the reasons for substantial defaults in the payment to the depositors, debenture holders, shareholders (in case of non-payment of declared dividends) and creditors;
- (19) to review the functioning of the whistle blower mechanism;
- (20) approval of appointment of Chief Financial Officer (i.e. the whole time Finance Director or any other person heading the finance function or discharging that function) after assessing the qualifications, experience and background, etc. of the candidate;
- (21) reviewing the utilization of loans and/or advances from/investment by the holding company in the subsidiary exceeding rupees 100 crore or 10% of the asset size of the subsidiary, whichever is lower including existing loans / advances / investments existing as on the date of coming into force of this provision;

- (22) to review the compliance with the provisions of Regulation 9A of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 at least once in a financial year and to verify that the systems for internal control are adequate and are operating effectively;
- (23) To consider and comment on rationale, cost-benefits and impact of schemes involving merger, demerger, amalgamation etc., on the listed entity and its shareholders;
- (24) to carry out any other function as is mentioned in the terms of reference of the Audit Committee.

**Audit Committee shall mandatorily review the following information:**

- (1) management discussion and analysis of financial condition and results of operations;
- (2) management letters / letters of internal control weaknesses issued by the statutory auditors;
- (3) internal audit reports relating to internal control weaknesses; and
- (4) the appointment, removal and terms of remuneration of the Chief Internal Auditor shall be subject to review by the audit committee;
- (5) statement of deviations:
  - (a) quarterly statement of deviation(s) including report of monitoring agency, if applicable, submitted to stock exchange(s) in terms of Regulation 32(1) of the Listing Regulations;
  - (b) annual statement of funds utilized for purposes other than those stated in the offer document/prospectus/notice in terms of Regulation 32(7) of the Listing Regulations.

In addition to the above, the Audit Committee discharges all such other duties and functions generally indicated under the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Companies Act, 2013 and the Rules made thereunder.

**Attendance at the Audit Committee Meetings:-**

During the year the Audit Committee met 4 times with attendance of the members as under:-

30<sup>th</sup> May 2024      |    13<sup>th</sup> August 2024      |    23<sup>rd</sup> October 2024      |    04<sup>th</sup> February 2025

Name	Attended
SOMBIR SINGH	4
AMRUTABEN RAJANBHAI SOLANKI	4
NIMESHKUMAR MOHANBHAI PARMAR	4

**NOMINATION AND REMUNERATION COMMITTEE:**

Nomination and Remuneration Committee presently comprises of three members being MR. SOMBIR SINGH, MS NIMESHKUMAR ARMAR and MS. AMRUTABEN RAJANBHAI SOLANKI. There was one Committee meetings held on 04<sup>th</sup> February 2025 during the year and respectively all members present during the meeting.

**The terms of reference of the Committee:**

Pursuant to the SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2018, the Company has revised the terms of reference of the Committee. The revised terms of reference are:

- (1) formulation of the criteria for determining qualifications, positive attributes and independence of a director and recommend to the board of directors a policy relating to, the remuneration of the directors, key managerial personnel and other employees;
  - (1A) For every appointment of an independent director, the Nomination and Remuneration Committee shall evaluate the balance of skills, knowledge and experience on the Board and on the basis of such evaluation, prepare a description of the role and capabilities required of an independent director. The person recommended to the Board for appointment as an independent director shall have the capabilities identified in such description. For the purpose of identifying suitable candidates, the Committee may:
    - a. use the services of an external agencies, if required;
    - b. consider candidates from a wide range of backgrounds, having due regard to diversity; and
    - c. consider the time commitments of the candidates
- (2) formulation of criteria for evaluation of performance of independent directors and the board of directors;
- (3) devising a policy on diversity of board of directors;
- (4) identifying persons who are qualified to become directors and who may be appointed in senior management in accordance with the criteria laid down and recommend to the board of directors their appointment and removal;
- (5) whether to extend or continue the term of appointment of the independent director, on the basis of the report of performance evaluation of independent directors;
- (6) recommend to the board, all remuneration, in whatever form, payable to senior management;

- (7) to administer and supervise Employee Stock Options Schemes (ESOS) including framing of policies related to ESOS and reviewing grant of ESOS;
- (8) To review HR Policies and Initiatives;
- (9) Carrying out any other function as is mentioned in the terms of reference of the Nomination and Remuneration Committee.

In addition to the above, Nomination and Remuneration Committee discharges such duties and functions generally indicated under the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Companies Act, 2013 and Rules made thereunder.

#### **Nomination and Remuneration Policy:**

The Committee is in process of formulating Nomination and Remuneration Policy which determines criteria inter-alia qualification, positive attributes and independence of Directors for their appointment on the Board of the Company and payment of remuneration to Directors, Key Managerial Personnel and other Employees. The Committee shall consider the following attributes / criteria, whilst recommending to the Board the candidature for appointment as Director.

- Qualification, expertise and experience of the Directors in their respective fields;
- Personal, Professional or business standing;
- Diversity of the Board

In case of re-appointment of Non-Executive Directors, the Board shall take into consideration the performance evaluation of the Director and his engagement level.

#### **STAKEHOLDERS' RELATIONSHIP COMMITTEE:**

The Board of Directors of the Company has set up 'Stakeholders Relationship Committee' in order to align it with the provisions of Section 178 of the Companies Act, 2013. The Committee has been constituted to strengthen the investor relations and to inter-alia, look into issues relating to shareholders grievances pertaining to transfer of shares, non- receipt of declared dividends, non-receipt of Annual Report, issues concerning de-materialization etc.

This committee presently consists of three directors namely, MR. SOMBIR SINGH, MS. AMRUTABEN RAJANBHAI SOLANKI and MS. NIMESHKUMAR MOHANBHAI PARMAR.

During the year under review, the Committee met on 04<sup>th</sup> February 2025 and all the members have attended the meetings.

#### **Terms of reference of the Committee:**

Pursuant to the SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2018, the Company has revised the terms of reference of the Committee. The revised terms of reference are:

- (1) resolving the grievances of the security holders of the company including complaints related to transfer/transmission of shares, nonreceipt of annual report, non-receipt of declared dividends, issue of new/duplicate certificates, dematerialization / rematerialization of Shares and debentures, general meetings etc;
- (2) review of measures taken for effective exercise of voting rights by shareholders;
- (3) review of adherence to the service standards adopted by the company in respect of various services being rendered by the Registrar and Share Transfer Agent;
- (4) review of the various measures and initiatives taken by the company for reducing the quantum of unclaimed dividends and ensuring timely receipt of dividend warrants/annual reports/statutory notices by the shareholders of the company;
- (5) to look into the reasons for any defaults in the payment to the Depositors, Debenture holders, Shareholders (in case of non-payment of declared dividends) and Creditors;
- (6) carrying out any other function as is mentioned in the terms of reference of the Stakeholder's Relationship committee.

Details of Complaints / Queries received and redressed during 1st April, 2024 to 31st March, 2025:

Number of shareholders' complaints pending at the beginning of the year	Number of shareholders' complaints received during the year	Number of shareholders' complaints redressed during the year	Number of shareholders' complaints pending at the end of the year
Nil	Nil	NA	Nil

#### GENERAL BODY MEETINGS:

Location and time for last 3 years Annual General Meetings:-

Financial Year	Location	Date	Time A.M./ P.M.	Special Resolution
2023-24	Registered Office	28.09.2024	01.00 PM	None
2022-23	Registered Office	28.09.2023	11.00 AM	None
2021-22	Registered Office	27.09.2022	10.00 AM	None

No Extra Ordinary General Meeting Held during the year. No special resolution was required to be carried out through postal ballot during the last year. No resolution is proposed by postal ballot at the ensuing Annual general meeting.

#### MEANS OF COMMUNICATION:

The Company has submitted its quarterly, half yearly and yearly financial results to the Stock Exchanges as well as website of the company immediately after its approval by the Board. The Company did not send the half yearly report to the Shareholders of the Company.

#### GENERAL SHAREHOLDERS INFORMATION:

GENERAL SHAREHOLDERS INFORMATION:

Financial Year	1st April to 31st March		
Date and time of Annual General Meeting	Friday, 26 <sup>th</sup> September, 2025 03:00 PM		
Venue of Annual General Meeting	At Registered office of the company		
Dates of Book Closure	19.06.2025 to 26.09.2025		
Listing on Stock Exchange	BSE Limited, The Calcutta Stock Exchange Limited MSE India Limited.		
Stock Code and Scrip ID	539470		
Demat ISIN No.	INE051N01026		
Tentative Calendar for the 2024-25			
Quarterly Financial Results	Date of Board Meeting	Quarterly Financial Results	Date of Board Meeting
First Quarter Unaudited Results	Before 14.08.2024	Third Quarter Unaudited Results	Before 14.02.2025
Second Quarter Unaudited Results	Before 14.11.2024	Fourth Quarter Unaudited Results	Before 15.05.2025
In case company take Audited Results for the Whole Financial Year.	Before 30th May, 2025		

#### CATEGORIES OF SHAREOWNERS AS ON 31.03.2025:

Category	No. of Shares Held	Voting Strength (%)
Promoters	Nil	0.00
Foreign Portfolio Investors	5664940	1.42
Resident Individuals		
share capital up to Rs. 2 lakh	321267052	80.59
share capital in excess of Rs. 2 lakh	58375148	14.64
Non-Resident Indians (NRIs)	7002328	1.76
Bodies Corporate	817939	0.21
HUF	5415899	1.36
Firm	80,694	0.02
Total	398624000	100.00

**DISTRIBUTION OF SHAREHOLDING AS ON 31.03.2025:**

Share Balance	Holders	% of Total	Total Shares	% of Total
Upto 5000	186047	94.03	102576334	25.73
5001-10000	5907	2.99	45662510	11.46
10001-20000	3044	1.54	43733973	10.97
20001-30000	1034	0.52	25886806	6.49
30001-40000	472	0.24	16606138	4.17
40001-50000	368	0.19	17118869	4.29
50001-100000	640	0.32	47253522	11.85
100001 and above	357	0.18	99785848	25.03
<b>Total</b>	<b>197869</b>	<b>100</b>	<b>398624000</b>	<b>100</b>

**STOCK MARKET DATA:**

The monthly movement of Equity Share prices on BSE during the year is summarized below:

Month	Highest (Rs)	Lowest (Rs)	Month	Highest (Rs)	Lowest (Rs)
Apr-24	1.39	1.06	Oct-24	1.25	0.94
May-24	1.22	1.14	Nov-24	1.13	1.01
Jun-24	1.20	1.07	Dec-24	1.19	1.02
Jul-24	1.44	1.12	Jan-25	1.08	0.83
Aug-24	1.25	1.12	Feb-25	1.15	0.94
Sep-24	1.16	1.04	Mar-25	1.03	0.90

**REGISTRAR AND SHARE TRANSFER AGENT:**

M/s SATELLITE CORPORATE SERVICES PRIVATE LIMITED having its registered office situated at Satellite Corporate Services Pvt Ltd Office No 106-107, Dattani Plaza, East West Compound, Andheri Kurla Road, Safedpul Sakinaka, Mumbai, Maharashtra, 400072 is the Registrar & Share Transfer Agent for processing the transfer of securities issued by the Company.

**SHARE TRANSFER SYSTEM:**

Subject to documentation being in order, transfer requests of equity shares in physical form lodged with the Company/ Registrars are processed within 15 days from the date of receipt. Those who are desirous of holding their shares in the Company in dematerialized form have to approach their respective Depository Participant for dematerialization of their shares.

**DEMATERIALIZATION OF SHARES AND LIQUIDITY:**

The Equity Shares of your company are traded in compulsory dematerialization form by all investors. The company has entered into agreements with both existing Depositories National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL) enabling the investors to hold shares of the company in electronic form through the depository of their choice.

**UNCLAIMED DIVIDEND/ SHARES CERTIFICATES:**

The Company has not declared / paid any dividend in the past, hence, there is no unclaimed dividend as at the ended of financial year under review.

Further, as per Regulation 34(3) read with Schedule V of Listing Regulation, the details of the shares in the Suspense Account are as follows:-

Aggregate Number of Shareholders and the Outstanding Shares in the suspense account lying at the beginning of the year	Number of shareholders who approached the Company for transfer of shares from suspense account during the year	Number of shareholders to whom shares were transferred from suspense account during the year	Aggregate number of shareholders and the outstanding shares in the suspense account lying at the end of the year	That the voting rights on these shares shall remain frozen till the rightful owner of such shares claims the shares
NIL	NIL	NIL	NIL	NIL

**ADDRESS FOR CORRESPONDENCE:**

126/3/2, 75C, Park Street, 3rd Floor, Kamdhenu Building, Kolkata-700016.

**Investors Correspondence/ Complaints to be address to:**

MR. AMAN PATEL Director and Compliance Officer

E-mail: [shreeganeshbiotechindia ltd@gmail.com](mailto:shreeganeshbiotechindia ltd@gmail.com)



**DISCLOSURES:**

- There are no materially significant related partly transactions i.e. transactions of the Company of material natures, with its promoters, the directors or the managements, their subsidiaries or relatives etc., that may have potential conflict with interest of the Company at large.
- No penalties or strictures were imposed on the Company by the Stock Exchange or SEBI or any statutory authority, on any matter related to capital markers, during the last three years.
- The Company has complied with various rules and regulations prescribed by the Stock Exchange and SEBI during the last three years. No penalties or strictures have been imposed by them on the Company.
- The Company is not exposed to commodity price risk since it generally executes projects through its contractors.
- There were no instances of raising of funds through preferential allotment or qualified institutions placement as specified under Regulation 32 (7A) of the Listing Regulations.
- A certificate obtains from Practicing Company Secretary that none of the directors on the board of the company have been debarred or disqualified from being appointed or continuing as directors of companies by the Board/Ministry of Corporate Affairs.
- In terms of the amendments made to the Listing Regulations, the Board of Directors confirm that during the year, it has accepted all recommendations received from its mandatory committees.
- Disclosure with respect to demat suspense account/ unclaimed suspense account: Not applicable.
- During the financial year 2024-25, the total fees for all services paid by the Company, on consolidated basis, to statutory auditor and all entities in the network firm/network entity of statutory auditor was Rs. 29500/-.
- Disclosure by listed entity and its subsidiaries of 'Loans and advances in the nature of loans to firms/companies in which directors are interested: Not Applicable, as the Company has not given any loans and advances in the nature of loans to firms/companies in which Directors are interested by name and amount, during the year under review.

**Disclosures in relation to the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013:**

Number of complaints filed during the financial year:	Nil
Number of complaints disposed off during the financial year:	NA
Number of complaints pending as on end of the financial year:	NA

**CEO/CFO Certification:**

The Chief Executive Officer (CEO) and Chief Financial Officer (CFO) have issued certificate pursuant to the provisions of Regulation 17(8) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, certifying that the financial statements do not contain any materially untrue statement and these statements represent a true and fair view of the Company's affair. The said certificate is annexed and forms a part of the Annual Report.

**Certificate on Corporate Governance:**

A compliance certificate from Statutory Auditor pursuant to the requirements of Schedule V to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding compliance of conditions of Corporate Governance is attached.

**For and on Behalf of the Board  
For, SHREE GANESH BIO-TECH (INDIA) LIMITED**

**AMAN PATEL  
Chairman  
DIN: 08045836**

**Kolkata, 22<sup>nd</sup> May 2025**



**CEO / CFO CERTIFICATE**  
**(Regulation 17(8) and Part B of Schedule II of SEBI (Listing Obligations and Disclosure Requirements)**  
**Regulations, 2015**

To,  
The Board of Directors  
Shree Ganesh Biotech (India) Limited  
Kolkata

Dear Sir,

I, the undersigned, in my respective capacities as the Chief Financial officer of Shree Ganesh Biotech (India) Limited ("the Company") to the best of our knowledge and belief certify that:

- A. I have reviewed the Financial Statements and the Cash Flow Statement for the year ended 31st March, 2025 and based on my knowledge and belief, I state that:
- (1) these statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading;
  - (2) these statements together present a true and fair view of the listed entity's affairs and are in compliance with existing accounting standards, applicable laws and regulations.
- B. I further state that to the best of my knowledge and belief, no transactions entered into by the listed entity during the year which are fraudulent, illegal or violative of the listed entity's code of conduct.
- C. I accept responsibility for establishing and maintaining internal controls for financial reporting and that they have evaluated the effectiveness of internal control systems of the listed entity pertaining to financial reporting and we have disclosed to the auditors and the audit committee, deficiencies in the design or operation of such internal controls, if any, of which we are aware and the steps we have taken or propose to take to rectify these deficiencies.
- D. I have indicated, based on my evaluation, wherever applicable, to the Auditors' and the Audit Committee:
- (1) significant changes in internal control over financial reporting during the year, if any;
  - (2) significant changes, if any, in accounting policies during the year and that the same has been disclosed in the notes to the financial statements; and
  - (3) instances of significant fraud of which they have become aware and the involvement therein, if any, of the management or an employee having a significant role in the listed entity's internal control system over financial reporting.

Place: Kolkata  
Date: 22.05.2025

**KISHAN NAIDU**  
Chief Financial Officer

**CERTIFICATE OF COMPLIANCE WITH THE CODE OF CONDUCT FOR BOARD OF DIRECTORS**

To  
The Members of  
**SHREE GANESH BIO-TECH (INDIA) LIMITED**  
Kolkata

All the members of the Board and Senior Management Personnel have affirmed compliance with the Code of Conduct in respect of the financial year ended March 31, 2025.

**For and on Behalf of the Board**  
**For, SHREE GANESH BIO-TECH (INDIA) LIMITED**

**AMAN PATEL**  
Chairman  
DIN: 08045836

Kolkata, 22<sup>nd</sup> May 2025

**Independent Auditors' Certificate on Compliance with the Corporate Governance requirements under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

---

**To The Members of Shree Ganesh Bio-Tech (India) Limited**

We have examined the compliance of conditions of Corporate Governance by **M/s. Shree Ganesh Bio-Tech (India) Limited** ("the company") for the year ended March 31, 2024, as stipulated in Schedule V and other relevant provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ["SEBI (LODR) Regulations 2015"].

The compliance of condition of Corporate Governance is the responsibility of the management. Our examination was limited to procedures and implementation thereof, adopted by the Company for ensuring the compliance conditions of Corporate Governance. It is neither an audit nor an expression of opinion on the financial statements of the Company.

In our opinion and to the best of our information and according to the explanations given to us, and based on the representations made by the Directors and the management, we certify that the Company has complied with the conditions of Corporate Governance as stipulated in the above mentioned Listing Regulations, as applicable.

We further state that such compliance is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company.

**Restrictions on Use**

This certificate is issued solely for the purpose of complying with the aforesaid Regulations and may not be suitable for any other purpose.

**For, BIPIN & CO.,  
CHARTERED ACCOUNTANTS  
FRN: 101509 W**

**CA AMIT SHAH  
PARTNER  
M. No.: 126337  
UDIN: 25126337BMLICR8550**

**PLACE: VADODARA  
DATE: 22.05.2025**

## **INDEPENDENT AUDITORS' REPORT**

### **TO THE MEMBERS OF SHREE GANESH BIO-TECH (INDIA) LIMITED**

#### **Report on the Audit of the Standalone Financial Statements**

##### **Opinion**

We have audited the standalone financial statements of **SHREE GANESH BIO-TECH (INDIA) LIMITED** ("the Company"), which comprise the Standalone Balance Sheet as at 31 March 2025, and the Standalone Statement of Profit and Loss (including other comprehensive income), Standalone Statement of Changes in Equity and Standalone Statement of Cash Flows for the year then ended, and notes to the standalone financial statements, including a summary of the significant accounting policies and other explanatory information (hereinafter referred to as "the standalone financial statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31 March 2025, and profit and other comprehensive income, changes in equity and its cash flows for the year ended on that date.

##### **Basis of Opinion**

We conducted our audit of the standalone financial statements in accordance with the Standards on Auditing specified under section 143(10) of the Act (SAs). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the independence requirements that are relevant to our audit of the standalone financial statements under the provisions of the Act and the Rules made thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the standalone financial statements.

##### **Key Audit Matters**

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the standalone financial statements of the current period. These matters were addressed in the context of our audit of the standalone financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

##### **Other Information**

The Company's management and Board of Directors are responsible for the other information. The other information comprises the information included in the Company's annual report, but does not include the standalone financial statements and our auditors' report thereon.

Our opinion on the standalone financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the standalone financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information; we are required to report that fact. We have nothing to report in this regard.

### **Management's Responsibility for the Standalone Financial Statements**

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Act with respect to the preparation of these Standalone Financial Statements that give a true and fair view of the financial position, financial performance including other comprehensive income, cash flows and changes in equity of the Company in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards (Ind AS) specified under Section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgements and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial Statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Standalone Financial Statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

### **Auditor's Responsibilities for the Audit of the Standalone Financial Statements**

Our objectives are to obtain reasonable assurance about whether the standalone financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's

ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the standalone financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the Standalone Financial Statements for the financial year ended March 31, 2024 and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

## **Report on Other Legal and Regulatory Requirements**

1. As required by section 143(3) of the Act, we report that:
  - a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit.
  - b) In our opinion proper books of account as required by law have been kept by the Company so far as appears from our examination of those books.
  - c) In absence of any branch office, the report on the accounts of branch office of the company audited under sub Sec. 8 by a person other than the Companies Auditor is not applicable.
  - d) The Balance Sheet, the Statement of Profit and Loss including Other Comprehensive Income, Statement of Changes in Equity and the Statement of Cash Flow dealt with by this Report are in agreement with the relevant books of account.
  - e) In our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014 and the Companies (Accounting Standards) Amendment Rules, 2016.

- f) On the basis of written representations received from the directors as on 31 March, 2025, taken on record by the Board of Directors, none of the directors is disqualified as on 31 March, 2025, from being appointed as a director in terms of Section 164(2) of the Act.
- g) There is no qualification, reservation or adverse remark relating to the maintenance of accounts and other matters connected there with.
- h) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "**Annexure A**". Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the Company's internal financial controls over financial reporting.
- i) In our opinion and according to the information and explanations given to us, No remuneration paid by the Company to its directors during the current year.
- j) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, as amended, in our opinion and to the best of our information and according to the explanations given to us:
  - i) The Company does not have any pending litigations which would impact its financial position.
  - ii) The Company did not have any long-term contracts including derivatives contracts for which there were any material foreseeable losses.
  - iii) There were no amounts which required to be transferred to the Investor Education and Protection Fund by the Company.
  - iv)
    1. The management has represented that, to the best of its knowledge and belief, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
    2. The management has represented that, to the best of its knowledge and belief, no funds have been received by the Company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and
    3. Based on the audit procedures conducted by us, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) contain any material misstatements.
  - v) No dividend declared or paid during the year by the Company.

vi) Based on our examination which included test checks, the Company has used an accounting software for maintaining its books of account which has a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the software. Further, during the course of our audit we did not come across any instance of audit trail feature being tampered with.

2. As required by the Companies (Auditor's Report) Order, 2020 ("the Order") issued by the Central Government in terms of Section 143(11) of the Act, we give in "**Annexure B**" a statement on the matters specified in paragraphs 3 and 4 of the Order

**For, BIPIN & CO.**  
**CHARTERED ACCOUNTANTS**  
**FRN: 101509 W**

**CA AMIT SHAH**  
**PARTNER**  
**M. No.: 126337**  
**UDIN: 25126337BMLICR8550**

**PLACE: VADODARA**  
**DATE: 22.05.2025**

## **Annexure "A" to the Auditors' Report**

### **Report on the internal financial controls with reference to the aforesaid standalone financial statements under section 143(3)(i) of the Companies Act, 2013**

---

We have audited the internal financial controls with reference to financial statements of **SHREE GANESH BIO-TECH (INDIA) LIMITED** ("the Company") as of March 31, 2025 in conjunction with our audit of the Ind AS financial statements of the Company for the year ended on that date.

#### **Management's Responsibility for Internal Financial Controls**

The Company's management and the Board of Directors are responsible for establishing and maintaining internal financial controls based on the internal financial controls with reference to standalone financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to the Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013 (hereinafter referred to as "the Act").

#### **Auditors' Responsibility**

Our responsibility is to express an opinion on the Company's internal financial controls with reference to standalone financial statements based on our audit. We conducted our audit in accordance with the Guidance Note and the Standards on Auditing, prescribed under Section 143(10) of the Act, to the extent applicable to an audit of internal financial controls with reference to standalone financial statements. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to standalone financial statements were established and maintained and whether such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to financial statements and their operating effectiveness. Our audit of internal financial controls with reference to financial statements included obtaining an understanding of internal financial controls with reference to financial statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the Auditors' judgment, including the assessment of the risks of material misstatement of the standalone financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

#### **Meaning of Internal Financial Controls over Financial Reporting**

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.



**Inherent Limitations of Internal Financial Controls over Financial Reporting**

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

**Opinion**

In our opinion, the Company has, in all material respects, adequate internal financial controls with reference to standalone financial statements and such internal financial controls were operating effectively as at 31 March 2024, based on the internal financial controls with reference to standalone financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India (the "Guidance Note").

**For, BIPIN & CO.  
CHARTERED ACCOUNTANTS  
FRN: 101509 W**

**CA AMIT SHAH  
PARTNER  
M. No.: 126337  
UDIN: 25126337BMLICR8550**

**PLACE: VADODARA  
DATE: 22.05.2025**

## **ANNEXURE "B" TO THE AUDITORS' REPORT**

---

**The Annexure referred to in paragraph 2 under 'Report on Other Legal and Regulatory Requirements' section of Our Report of even date to the members of M/s SHREE GANESH BIO-TECH (INDIA) LIMITED on the accounts of the company for the year ended 31<sup>st</sup> March, 2025.**

1. In respect of the Company's fixed assets:

a) (1) The Company has maintained proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment.

(2) The company does not have any intangible assets.

b) The Company has a program of verification to cover all the items of Property, Plant and Equipment in a phased manner which, in our opinion, is reasonable having regard to the size of the Company and the nature of its assets. Pursuant to the program, certain Property, Plant and Equipment were physically verified by the management during the year. According to the information and explanations given to us, no material discrepancies were noticed on such verification.

c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the title deeds of immovable properties (other than immovable properties where the Company is the lessee and the lease agreements are duly executed in favor of the lessee) disclosed in the standalone financial statements are held in the name of the Company.

d) According to the information and explanations given to us, the Company has not revalued its Property, Plant and Equipment or intangible assets or both during the year.

e) According to the information and explanation given to us, the Company has no proceedings pending for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 and rules made thereunder.

2. a) As explained to us, inventories have been physically verified during the year by the management at reasonable intervals. In our opinion, the frequency of verification is reasonable. As informed to us there were no material discrepancies noticed on verification between the physical stocks and the book records and any discrepancies found has been properly dealt within the books of accounts.

b) The Company has not been sanctioned working capital limits in excess of ₹ 5 crore, in aggregate, at any points of time during the year, from banks or financial institutions on the basis of security of current assets and hence reporting under this clause of the Order is not applicable.

3. In respect of the loans, secured or unsecured, granted by the company to companies, firms or other parties covered in the register-maintained u/s. 189 of the Companies Act, 2013:

(1) As per the information furnished, the company has made investment in other concerns, however the company has not granted any loans or advances, secured or unsecured or any guarantee to the companies, firms and other parties covered in the register maintained under section 189 of the Companies Act, 2013. Accordingly, the provisions of clause (iii)(a), (c) to (f) of the order are not applicable to the company.

(2) The Investments made are not prejudicial to the Company's Interest.

4. In our opinion and according to the information and explanations given to us, the Company has complied with the provisions of section 185 and 186 of the Act, with respect to the loans and investments made.
5. The Company has not accepted any deposit or amounts which are deemed to be deposits. Hence, reporting under clause 3(v) of the Order is not applicable.
6. As informed to us, Central government has not prescribed maintenance of cost records under sub-section (1) of section 148 of the Companies Act, in respect of products of the company. Hence, reporting under clause (vi) of the Order is not applicable to the Company.
7. In respect of Statutory dues:
  - a) The Company is generally regular in depositing with appropriate authorities undisputed statutory dues including Provident Fund, Employees' State Insurance, Income Tax, Wealth Tax, Custom Duty, Goods and Service Tax, Cess and other material statutory dues applicable to it. According to the information and explanations given to us, no undisputed amounts payable in respect of outstanding statutory dues were in arrears as at March 31, 2025 for a period of more than six months from the date they became payable.
  - b) According to the information and explanations given to us, following disputed amounts are payable as at March 31, 2025.

S.No.	Name of the statute	Nature of dues	As 31/3/2025 (Rs. In lakhs)	At
1	Income Tax Act, 1961	Income Tax	22.84	

8. According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not surrendered or disclosed any transactions, previously unrecorded as income in the books of account, in the tax assessments under the Income-tax Act, 1961 as income during the year.
9. In our opinion and according to the information and explanations given to us, in respect of Company's Borrowings:
  - a) The Company has not defaulted in repayment of loans or other borrowings or in the payment of interest thereon to any lender.
  - b) The Company is not a declared willful defaulter by any bank or financial institution or other lender.
  - c) The Company has not obtained any term loans during the year.
  - d) The funds raised on short term basis have not been utilized for long term purposes.
  - e) The Company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiary.
  - f) The Company has not raised loans during the year on the pledge of securities held in its subsidiary.

10. a) The Company has not raised moneys by way of initial public offer or further public offer (including debt instruments) during the year and hence reporting under clause 3(x)(a) of the Order is not applicable.
- b) During the year, the Company has not made any preferential allotment or private placement of shares or convertible debentures (fully or partly or optionally) and hence reporting under clause 3(x)(b) of the Order is not applicable.
11. In respect of fraud by the Company or on the Company:
- a) Based on examination of the books and records of the Company and according to the information and explanations given to us, considering the principles of materiality outlined in Standards on Auditing, we report that no fraud by the Company or on the Company has been noticed or reported during the course of the audit.
- b) According to the information and explanations given to us, no report under sub-section (12) of Section 143 of the Companies Act, 2013 has been filed by the auditors in Form ADT-4 as prescribed under Rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government.
- c) There have been no whistle-blower complaints received during the year by the company.
12. According to the information and explanations given to us, the Company is not a Nidhi Company. Accordingly, clause 3(xii) of the Order is not applicable.
13. In our opinion and according to the information and explanations given to us, all transactions with the related parties are in compliance with sections 177 and 188 of the Act, where applicable, and the details have been disclosed as required by the applicable Indian Accounting Standard (Ind AS)-24 Related Party Disclosures.
14. Based on information and explanations provided to us and our audit procedures, in our opinion, the Company has an internal audit system commensurate with the size and nature of its business.
15. In our opinion and according to the information and explanations given to us, the Company has not entered into any non-cash transactions with its directors or persons connected to its directors and hence, provisions of Section 192 of the Companies Act, 2013 are not applicable to the Company.
16. a) The Company is not required to be registered under Section 45- IA of the Reserve Bank of India Act, 1934. Accordingly, clause 3(xvi)(a) and (b) of the Order are not applicable.
- b) The Company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India. Accordingly, clause 3(xvi)(c) and (d) of the Order are not applicable.
17. According to the information and explanations given to us, the Company has not incurred cash losses in current and immediate preceding financial year.
18. According to the information and explanations given to us, there has been no resignation of the statutory auditors during the year.

19. According to the information and explanations given to us and on the basis of the financial ratios, ageing and expected dates of realisation of financial assets and payment of financial liabilities, other information accompanying the financial statements, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report that the Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.
20. a) As per the information and explanation given to us, provisions of sec. 135 being corporate social responsibility are not applicable to the company, as the company does not have:
- net worth of rupees five hundred crore or
  - turnover of rupees one thousand crore or more or
  - a net profit of rupees five crore or more during the immediately preceding financial year.
- b) Provisions of sec. 135(5) and (6) of the Companies Act relating to unspent amount and transfer thereof to special account are not applicable to the Company.

**For, BIPIN & CO.**  
**CHARTERED ACCOUNTANTS**  
**FRN: 101509 W**

**CA AMIT SHAH**  
**PARTNER**  
**M. No.: 126337**  
**UDIN: 25126337BMLICR8550**

**PLACE: VADODARA**  
**DATE: 22.05.2025**

<b>Shree Ganesh Biotech (India) Ltd</b> <b>CIN:- L70101WB1982PLC121196</b> Regd. Office: 6th Floor, Premises - 126,3/2, 75C, Park Street, 3rd Floor, Kamdhenu Building, Kolkata, West Bengal, 700016			
<b>BALANCE SHEET AS AT 31ST MARCH, 2025</b>			
(Rs. Lakhs)			
Particulars	Note Ref	As at March 31, 2025	As at March 31, 2024
ASSETS			
(1) Non-current Assets			
(a) Property, plant and equipment	2	0.19	0.24
(b) Other Intangible Assets		-	-
(c) Financial Assets			
(i) Investments	3	915.00	-
(ii) Loans And Advances Long Term	4	5,094.09	6,988.82
(iii) Other Financial Assets		-	-
(d) Deferred Tax Assets (Net)		-	-
(e) Other non-current assets		-	-
		<b>6,009.28</b>	<b>6,989.06</b>
(2) Current Assets			
(a) Inventories	5	288.99	-
(b) Financial Assets			
(i) Trade Receivables	6	-	330.32
(ii) Cash & Cash Equivalents	7	1.31	42.80
(iii) Loans And Advances Short Term		-	-
(c ) Current Tax Assets (Net)		-	-
(d) Other Current Assets	8	49.17	-
		<b>339.47</b>	<b>373.13</b>
TOTAL ASSETS		<b>6,348.76</b>	<b>7,362.18</b>
EQUITY AND LIABILITIES			
EQUITY			
(a) Equity Share Capital	9	3,986.24	3,986.24
(b) Other Equity	10	2,339.35	2,311.51
TOTAL EQUITY		<b>6,325.59</b>	<b>6,297.75</b>
LIABILITIES			
(1) Non - Current Liabilities			
(a) Financial Liabilities			
(i) Borrowings		-	-
(b) Deferred Tax liability (Net)		-	-
		-	-
(2) Current Liabilities			
(a) Financial Liabilities			
(i) Trade Payables	11	-	1,036.02
(b) Other Current Liabilities	12	23.17	28.42
		<b>23.17</b>	<b>1,064.44</b>
TOTAL EQUITY AND LIABILITIES		<b>6,348.76</b>	<b>7,362.18</b>
Statement of significant accounting policies and other explanatory notes form part of the balance sheet and statement of profit and loss.			
As per our Report of even date		For and on behalf of the Board	
<b>For, BIPIN &amp; CO.</b> Chartered Accountants FRN: 101509 W			
<b>CA AMIT SHAH</b> (Partner) M. No.: 126337 UDIN:25126337BMLICR8550 Place: Vadodara Date: 20.05.2025		<b>AMAN PATEL</b> Whole Time Director DIN: 08483544	<b>KISHAN NAIDU</b> Director & CFO DIN: 08662664

**Shree Ganesh Biotech (India) Ltd**
**CIN:- L70101WB1982PLC121196**

Regd. Office: 6th Floor, Premises - 126,3/2, 75C, Park Street, 3rd Floor, Kamdhenu Building, Kolkata, West Bengal, 700016

**STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED 31ST MARCH, 2025**

(Rs. Lakhs)

Particulars	Note No	F.Y. 2024-25	F.Y. 2023-24
I. Revenue from Operations	13	2,295.76	2,027.77
II. Other Income	14	144.09	105.63
<b>III. Total Revenue (I + II)</b>		<b>2,439.85</b>	<b>2,133.40</b>
<b>IV. Expenses:</b>			
Cost of Material Consumed		-	-
Purchase of Stock-in-Trade	15	2,553.09	2,003.13
Change in inventories of finished goods & work in progress	16	288.99	-
Employee Benefit Expense	17	9.76	18.43
Financial costs	18	0.00	0.01
Depreciation & Amortisation	19	0.05	0.05
Other Expenses	20	127.25	26.28
<b>IV. Total Expenses</b>		<b>2,401.16</b>	<b>2,047.91</b>
V. Profit before tax and Exceptional items:	(III - IV)	38.69	85.49
VI. Exceptional items:		-	-
VII. Profit Before Tax		38.69	85.49
VIII. Tax Expense:			
(1) Current Tax			
- Income Tax		10.85	23.42
(2) Earlier Year Tax		-	-
- Short/(Excess) Provision of Tax		-	-
(3) Deferred Tax		-	-
(4) MAT Credit entitlement		-	-
IX. Profit/(Loss) for the period from Continuing Operations	(V - VI)	<b>27.84</b>	<b>62.07</b>
<b>X. Other Comprehensive Income</b>			
A (i) Items that will not be reclassified to profit or loss		-	-
(ii) Tax relating to items that will not be reclassified to profit or loss		-	-
<b>Other Comprehensive Income for the year, net of tax</b>		-	-
<b>XI. Total Comprehensive Income for the period (VII+VIII)</b>	(VI + VII)	<b>27.84</b>	<b>62.07</b>
<b>XII. Earning per equity share (Basic and Diluted)</b>		<b>0.01</b>	<b>0.02</b>
Significant Accounting Policies & Notes on Accounts 18			
The schedule referred above to form an integral part of the Profit & Loss in our report of even date.			
<b>For, BIPIN &amp; CO.</b>		For and on Behalf of the Board	
Chartered Accountants			
FRN: 101509 W			
<b>CA AMIT SHAH</b>		<b>AMAN PATEL</b>	<b>KISHAN NAIDU</b>
(Partner)		Whole Time Director	Director & CFO
M. No.: 126337		DIN: 08483544	DIN: 08662664
UDIN:25126337BMLICR8550			
Place: Vadodara			
Date: 20.05.2025			

**Shree Ganesh Biotech (India) Ltd**  
**CIN:- L70101WB1982PLC121196**

Regd. Office: 6th Floor, Premises - 126,3/2, 75C, Park Street, 3rd Floor, Kamdhenu Building, Kolkata, West Bengal, 700016

**CASH FLOW STATEMENT FOR THE YEAR ENDED 31ST MARCH 2025**

Particulars	31.03.2025 (Rs. Lakhs)	31.03.2024 (Rs. Lakhs)
<b>A. CASH FLOW FROM OPERATING ACTIVITIES:</b>		
Profit before tax and extra ordinary items	38.69	85.49
Adjustment For :		
Share of (profit)/loss from investment in partnership firm	-	-
Depreciation/amortization on continuing operation	0.05	0.05
Interest expenses	-	-
<b>Operating profit before working capital changes</b>	<b>38.74</b>	<b>85.55</b>
<b>Movement in Working Capital :</b>		
Increase/(decrease) in Inventory	- 288.99	-
Increase/(decrease) in Trade receivables	330.32	1,602.52
Increase/(decrease) in Short Term Loan & Advances	-	-
Increase/(decrease) in Current Liabilities	- 5.25	- 39.17
Increase/(decrease) in Trade Payable	- 1,036.02	- 613.00
Increase/(decrease) in Other Current Assets	- 49.17	- 3.30
Direct taxes paid (net of refunds)	- 10.85	- 23.42
<b>Net Cash Flow from Operating Activities(A)</b>	<b>- 1,021.21</b>	<b>1,015.77</b>
<b>B. CASH FLOW FROM INVESTING ACTIVITIES</b>		
Investments	- 915.00	-
Purchase / Sale of Fixed Assets	-	-
Increase/(decrease) in Long Term Loan & Advances	1,894.72	- 1,020.99
<b>Net Cash Flow from Investing Activities(B)</b>	<b>979.72</b>	<b>- 1,020.99</b>
<b>C. CASH FLOW FROM FINANCING ACTIVITIES</b>		
Proceed (Repayment) from long term borrowing	-	-
Proceed (Repayment) from short term borrowing	-	-
Proceed from Preferential Warrants	-	-
<b>Net Cash Flow from Financing Activities(C)</b>	<b>-</b>	<b>-</b>
Net increase/(decrease) in cash & cash equivalents(A+B+C)	- 41.49	- 5.21
Cash and Cash equivalents (Opening Balance)	42.80	48.01
<b>Cash and Cash equivalents (Closing Balance)</b>	<b>1.31</b>	<b>42.80</b>

Previous year figure have been regrouped/ reclassified wherever necessary

As per our report of even date

**For, BIPIN & CO.**

Chartered Accountants

FRN: 101509 W

For and on Behalf of the Board

**CA AMIT SHAH**

(Partner)

M. No.: 126337

UDIN:25126337BMLICR8550

Place: Vadodara

Date: 20.05.2025

**AMAN PATEL**

Whole Time Director

DIN: 08483544

**KISHAN NAIDU**

Director & CFO

DIN: 08662664



**10(A) Equity Share Capital**

Equity share capital of face value ` 1.00 each	No. of Shares	(Figures in Rs. Lakhs)
Balance as at April 1, 2023	<b>398,624,000</b>	<b>3,986.24</b>
Changes in equity share capital during the year	-	-
Balance as at March 31, 2024	<b>398,624,000</b>	<b>3,986.24</b>
Changes in equity share capital during the year	-	-
Balance as at March 31, 2025	<b>398,624,000</b>	<b>3,986.24</b>

The Company has only one class of equity shares having a par value of Rs.1 per share. Each holder of equity shares is entitled to one vote per share.

**10(B)**

	Other equity			Other Comprehensive Income	
	Capital Reserve	Securities Premium	Retained Earnings	Equity Instrument through OCI	Total
Balance at the beginning of the reporting period on 1st April 2023	-	543.28	1,706.15	-	<b>2,249.43</b>
Profit for the period	-	-	62.07	-	<b>62.07</b>
Other Comprehensive Income for the year	-	-	-	-	-
Balance as on 31st March 2024	-	543.28	1,768.23	-	<b>2,311.51</b>
Profit for the period	-	-	27.84	-	<b>27.84</b>
Other Comprehensive Income for the year	-	-	-	-	-
Balance as on 31st March 2025	-	543.28	1,796.07	-	<b>2,339.35</b>

Statement of significant accounting policies and other explanatory notes form part of the balance sheet and statement of profit and loss.

As per our Report of even date  
**For, BIPIN & CO.**  
Chartered Accountants  
FRN: 101509 W

For and on behalf of the Board

**CA AMIT SHAH**  
(Partner)  
M. No.: 126337  
UDIN:25126337BMLICR8550  
Place: Vadodara  
Date: 20.05.2025

**AMAN PATEL**  
Whole Time Director  
DIN: 08483544

**KISHAN NAIDU**  
Director & CFO  
DIN: 08662664

**NON-CURRENT ASSETS****NOTE 2 : PROPERTY, PLANT & EQUIPMENTS****(In Lakhs)**

<b>Particulars</b>	<b>Computer &amp; Printer</b>	<b>Air Conditioner</b>	<b>Total</b>
Gross Block			
As on 01/04/2023	0.17	0.56	0.73
Additions	0.00	0.00	0.00
Adjustments	0.00	0.00	0.00
As on 31/03/2024	0.17	0.56	0.73
Additions	0.00	0.00	0.00
Adjustments	0.00	0.00	0.00
As on 31/03/2025	0.17	0.56	0.73
Accumulated Depreciation	0.00	0.00	0.00
As on 01/04/2023	0.17	0.27	0.44
For the year 2023-24	0.00	0.05	0.05
Adjustments	0.00	0.00	0.00
As on 31/03/2024	0.17	0.32	0.49
For the year 2024-25	0.00	0.05	0.05
Adjustments	0.00	0.00	0.00
As on 31/03/2025	0.17	0.37	0.54
Net Block as on 31/03/2025	0.00	0.19	0.19
Net Block as on 31/03/2024	0.00	0.24	0.24

**Shree Ganesh Biotech (India) Ltd**  
**CIN:- L70101WB1982PLC121196**

Regd. Office: 6th Floor, Premises - 126,3/2, 75C, Park Street, 3rd Floor, Kamdhenu Building, Kolkata, West Bengal, 700016

**NOTE 3 : FINANCIAL ASSETS -INVESTMENTS**

(Rs. Lakhs)

Particulars	As at March 31, 2025	As at March 31, 2024
<b>Investments in Equity Instruments</b>		
<b>(i) Quoted Equity Shares</b>		
(At Fair value through OCI)	-	-
<b>Total (i)</b>	-	-
<b>(ii) Unquoted Preference Shares</b>		
TDPL Pref. Shares	<b>915.00</b>	-
<b>Total (ii)</b>	<b>915.00</b>	-
<b>(iii) Investment in Partnership Firm</b>		
(at Cost)		
<b>Total (iii)</b>	-	-
<b>Total(i+ii+iii)</b>	<b>915.00</b>	-

**NOTE 4 : FINANCIAL ASSETS -LOANS**

Particulars	As at March 31, 2025	As at March 31, 2024
<b>Loans to Others:</b>		
<b>(Unsecured, Considered Good)</b>	5,094.09	6,988.82
<b>Total</b>	<b>5,094.09</b>	<b>6,988.82</b>

**CURRENT ASSETS**

**NOTE 5 : FINANCIAL ASSETS- INVENTORIES**

Particulars	As at March 31, 2025	As at March 31, 2024
<b>Finished Goods</b>	288.99	-
<b>Total</b>	<b>288.99</b>	-

**NOTE 6 : FINANCIAL ASSETS- TRADE RECEIVABLES**

Particulars	As at March 31, 2025	As at March 31, 2024
<b>UNSECURED, CONSIDERED GOOD:</b>		
(a) Outstanding for a period exceeding six months from the date they are due for payment	-	330.32
	-	-
Less: Provision for doubtful Debts	-	-
<b>Total</b>	-	<b>330.32</b>

**NOTE 6 .1 Trade Receivables Ageing Schedule:****As March 31,2025**

Prs	Unbilled Dues	Not due	Outstanding for following periods from due date of payment					Total
			Less than 6 Months	6 Months -1 Year	1-2 years	2-3 years	More Than 3 Years	
Undisputed Trade receivables - Considered Good	-	-	-	-		-	-	-
Undisputed Trade receivables - which have significant increase in risk	-	-	-	-	-	-	-	-
Undisputed Trade receivables - credit impaired	-	-	-	-	-	-	-	-
Disputed Trade receivables - Considered Good	-	-	-	-	-	-	-	-
Disputed Trade receivables - which have significant increase in risk	-	-	-	-	-	-	-	-
Disputed Trade receivables - credit impaired	-	-	-	-	-	-	-	-
<b>Total</b>	-	-	-	-	-	-	-	-

**As March 31,20234**

Prs	Unbilled Dues	Not due	Outstanding for following periods from due date of payment					Total
			Less than 6 Months	6 Months - 1 Year	1-2 years	2-3 years	More Than 3 Years	
Undisputed Trade receivables - Considered Good	-	-	<b>330.32</b>	-	-	-	-	<b>330.32</b>
Undisputed Trade receivables - which have significant increase in risk	-	-	-	-	-	-	-	-
Undisputed Trade receivables - credit impaired	-	-	-	-	-	-	-	-

Disputed Trade receivables - Considered Good	-	-	-	-	-	-	-	-
Disputed Trade receivables - which have significant increase in risk	-	-	-	-	-	-	-	-
Disputed Trade receivables - credit impaired	-	-	-	-	-	-	-	-
<b>Total</b>	-	-	<b>330.32</b>	-	-	-	-	<b>330.32</b>

**NOTE 7 :FINANCIAL ASSETS- CASH AND CASH EQUIVALENT**

Particulars	As at March 31, 2025	As at March 31, 2024
Balances with Bank	0.96	42.35
- Current account		
Cash in hand		
<b>Total</b>	<b>1.31</b>	<b>42.80</b>

**NOTE 8 : Other Current Assets**

Particulars	As at March 31, 2025	As at March 31, 2024
Other Receivable	49.17	-
Prepaid Expenses		
<b>Total</b>	<b>49.17</b>	<b>-</b>

**NOTE 9: EQUITY SHARE CAPITAL** (Rs. Lakhs)

	As at March 31, 2025		As at March 31, 2024	
<b>A. Authorised:</b> 40,00,00,000 equity shares of Rs. 1/- each	-	4,000.00	-	4,000.00
<b>Total</b>	-	<b>4,000.00</b>	-	<b>4,000.00</b>
<b>B. Issued, Subscribed &amp; Fully Paid-up:</b> 39,86,24,000 equity shares of Rs. 1/- each	-	3,986.24	-	3,986.24
<b>Total</b>	-	<b>3,986.24</b>	-	<b>3,986.24</b>

**Disclosures:**

**(i) Details of Shareholding in excess of 5%**

Name of Shareholder	As at March 31, 2025		As at March 31, 2024	
	Number of Shares held	%	Number of Shares held	%

**NOTE 10 : OTHER EQUITY**

(In `)

Particulars	As at March 31, 2025	As at March 31, 2024
(a) Capital reserve	-	-
(b) Security Premium	543.28	543.28
(c) Retained Earnings	1,796.07	1,768.23
(d) Money Received against share warrants	-	-
<b>Total</b>	<b>2,339.35</b>	<b>2,311.51</b>

**CURRENT LIABILITIES**

**NOTE 11 : FINANCIAL LIABILITIES-TRADE PAYABLES**

Particulars	As at March 31, 2025	As at March 31, 2024
Total outstanding dues of MSME	-	-
Total outstanding dues of other than MSME	-	1,036.02
Due to Others	-	-
Trade payable: Others	-	-
<b>Total</b>	-	<b>1,036.02</b>

**(11.1) Trade Payables ageing schedule:**

As at March 31, 2025						
Particulars	Not due	Outstanding for following periods from due date of Payment				Total
		Less than 1 year	1-2 years	2-3 years	>3	
MSME	-	-	-	-	-	-
Others	-	-	-	-	-	-
Disputed dues - MSME	-	-	-	-	-	-
Disputed dues - Others	-	-	-	-	-	-
Unbilled dues	-	-	-	-	-	-
Total	-	-	-	-	-	-

**As at March 31, 2024**

Particulars	Not due	Outstanding for following periods from due date of Payment				Total
		Less than 1 year	1-2 years	2-3 years	>3	
MSME	-	-	-	-	-	-
Others	-	411.02	-	625.00	-	1,036.02
Disputed dues - MSME	-	-	-	-	-	-
Disputed dues - Others	-	-	-	-	-	-
Unbilled dues	-	-	-	-	-	-
Total	-	411.02	-	625.00	-	1,036.02

**NOTE 12: OTHER CURRENT LIABILITIES**

Particulars	As at March 31, 2025	As at March 31, 2024
Provisions For Tax	10.85	23.42
Other Payables	12.32	5.00
Duties & Taxes	-	-
<b>Total</b>	<b>23.17</b>	<b>28.42</b>

(In Rs. Lakhs)

**Note : 13 Revenue from Operations**

Sr. No	Particulars	F.Y. 2024-25	F.Y. 2023-24
1	Sales	554.01	2,027.77
2	Sales Stock	1,741.75	-
	<b>Total</b>	<b>2,295.76</b>	<b>2,027.77</b>

**Note : 14 Other Income**

Sr. No	Particulars	F.Y. 2024-25	F.Y. 2023-24
1	Profit /(Loss) from Partnership Firm	-	-
2	Balances written-off	-	0.04
3	Dividend Received	0.28	-
4	Short Term Capital Gain	-	-
5	Interest received on Loan	143.82	105.59
6	Other Income	-	-
	<b>Total</b>	<b>144.09</b>	<b>105.63</b>

**Note : 15 Purchase of Stock**

Sr. No	Particulars	F.Y. 2024-25	F.Y. 2023-24
1	Purchase	535.74	2,003.13
2	Purchase Stock	2,017.34	-
	<b>Total</b>	<b>2,553.09</b>	<b>2,003.13</b>

**Note : 16 Change in Inventories**

Sr. No	Particulars	F.Y. 2024-25	F.Y. 2023-24
1	Inventories at the beginning of the year		
	Finished goods	-	-
	Work in Progress	-	-
	Inventories at the end of the year		
	Finished Goods	288.99	-
	Work in Progress	-	-
	<b>Total</b>	<b>- 288.99</b>	<b>-</b>

**Shree Ganesh Biotech (India) Ltd**  
**CIN:- L70101WB1982PLC121196**

Regd. Office: 6th Floor, Premises - 126,3/2, 75C, Park Street, 3rd Floor, Kamdhenu Building, Kolkata, West Bengal, 700016

**Notes Forming Part of the Profit and Loss Statement**

**Note : 17 Employment Benefit Expenses**

Sr. No	Particulars	F.Y. 2024-25	F.Y. 2023-24
1	Salaries & Wages	9.76	18.43
2	Staff Welfare	-	-
	<b>Total</b>	<b>9.76</b>	<b>18.43</b>

**Note : 18 Financial Cost**

Sr. No	Particulars	F.Y. 2024-25	F.Y. 2023-24
1	Interest Expense	-	-
2	Bank Charges	0.00	0.01
	<b>Total</b>	<b>0.00</b>	<b>0.01</b>

**Note : 19 Depreciation & Amortisation**

Sr. No	Particulars	F.Y. 2024-25	F.Y. 2023-24
1	Depreciation on Tangible assests	0.05	0.05
2	Amortisation of Expenses Amalgamation Expenses	- -	- -
	<b>Total</b>	<b>0.05</b>	<b>0.05</b>

**Note : 20 Other Expenses**

Sr. No	Particulars	F.Y. 2024-25	F.Y. 2023-24
1	Annual Custody Fees	13.64	6.99
2	Advertisement Expense	0.22	0.65
3	Audit Fees	0.30	0.29
4	Balance Written Off	85.58	-
5	Demat Charges	2.31	-
6	E-Voting Expense	0.19	-
7	Income Tax Expense	2.01	7.56
8	Listing Compliance Fees	4.90	4.90
9	Loss from Future Contracts	9.14	-
10	Office Expense	-	0.15
11	Postage & Telegram Expense	0.07	0.04
12	Printing & Stationery Expense	0.17	-
13	Professional & Legal Fees	0.80	3.00
14	Rent	0.36	0.39
15	ROC Fees	0.10	-
16	SDD Software Fees	0.04	0.18
17	STT	2.40	-
18	Travelling Expense	5.01	2.14
19	Web Hosting Charges	0.04	-
	<b>Total</b>	<b>127.25</b>	<b>26.28</b>



**Shree Ganesh Biotech (India) Ltd**

CIN:- L70101WB1982PLC121196

Regd. Office: 6th Floor, Premises - 126,3/2, 75C, Park Street, 3rd Floor, Kamdhenu Building, Kolkata, West Bengal, 700016

**Note 21 : Financial Ratios**

Sr.	Type of Ratio	Numerator	Denominator	2024-25	2023-24	Variance (in %)	Remarks for variance more than 25%
1	Current Ratio (In times)	Current Assets	Current Liabilities	14.65	0.35	40.80	Increase in Current Asset
2	Debt-Equity Ratio (In times)	Total Debt	Total Equity	-	-	-	Not Applicable
3	Debt Service Coverage Ratio (In times)	Earnings before Interest, Depreciation and amortisation and after tax other adjustments like loss/profit on sale of Fixed assets etc.	Debt Service	-	-	-	Not Applicable
4	Return on Equity Ratio (%)	Net Profit after Tax	Average Total Equity	0.44%	0.99%	(55.35%)	Reduction in net profit
5	Inventory turnover Ratio (In times)	Revenue from operations	Average Inventories	-	-	-	Not Applicable
6	Trade Receivables turnover Ratio (In times)	Revenue from operations	Average Trade Receivables	13.90	0.00	97130524.26%	Reduction in Trade Receivable
7	Trade Payables turnover Ratio (In times)	Total purchases	Average Trade Payables	4.93	0.00	203,336.45	Reduction in Trade Payable
8	Net capital turnover Ratio (In times)	Revenue from operations	Working Capital	7.26	-2.93	-347.44%	Reduction in Working Capital
9	Net profit Ratio (%)	Net Profit after Tax	Revenue from operations	1.21%	3.06%	(60.38%)	Reduction in net profit
10	Return on Capital employed (%)	Profit before Interest, Exceptional Items and Tax	Total Capital Employed ((Total Equity + Total Debt + Deferred Tax Liabilities)/(Assets)	0.61%	1.36%	-54.94%	Reduction in net profit

**SHREE GANESH BIO-TECH (INDIA) LIMITED**  
**CIN: L70101WB1982PLC121196**

**Notes forming part of the financial statements**

---

**Basis of preparation**

The financial statements of the Company have been prepared in accordance with the generally accepted accounting principles in India (Indian GAAP). The company has prepared these financial statements to comply in all material respects with the accounting standards notified under Section 133 of the Companies Act, 2013, read together with paragraph 7 of the Companies (Accounts) Rules, 2014 and Companies (Accounting Standards) Amendment Rules, 2016. The financial statements have been prepared on an accrual basis and under the historical cost convention. The accounting policies adopted in the preparation of financial statements are consistent with those of previous year, except for the change in accounting policy explained below.

**Use of Estimates**

The preparation of financial statements in conformity with generally accepted accounting principles requires estimates and assumptions to be made that affect the reported amount of assets and liabilities on the date of the financial statements and the reported amount of revenue and expenses during the reporting period. Differences between actual results and estimates are recognised in the period in which the results are known / materialised.

**Note: 1 Significant Accounting Policies:**

**a) General:**

- i) Accounting policies not specifically referred to otherwise are in consistence with earlier year and in consonance with generally accepted accounting principles.
- ii) Expenses and income considered payable and receivable respectively are accounted for on accrual basis.

**b) Valuation of Inventories:** Inventories are valued at cost on FIFO Basis.

**c) Fixed assets and depreciation:**

- i) Fixed Assets are stated at cost of acquisition less accumulated depreciation and is inclusive of freight taxes, and incidental expenses relating to such acquisition.
- ii) No Depreciation is provided on Fixed Assets comprises of Office Guest House and Computer being not used in business.

**d) Investments:** There is no Investment made by the company.

**e) Foreign currency Transactions:** There is no foreign currency transaction.

**f) Retirement Benefits:** Provident fund and employees state insurance scheme contribution is not applicable to the company.

**g) Taxes on Income:**

**Current Tax:** Provision for Income-Tax is determined in accordance with the provisions of Income-tax Act 1961.

**Deferred Tax Provision:** Deferred tax is recognized, on timing difference, being the difference between the taxable incomes and accounting income that originate in one period and are capable of reversal in one or more subsequent periods.

- Note: 22** Balances of Sundry Debtors, Creditors, Loans and Advances are subject to confirmation and reconciliation.
- Note: 23** In the opinion of the Board of directors, the current assets, Loans & advances are approximately of the value stated if realized in the ordinary course of business. The provision of all known liabilities is adequate and not in excess of the amount reasonably necessary.
- Note: 24** No Remuneration paid to the directors during the year.
- Note: 25** No related party transaction were carried out during the year.
- Note: 26** there is no reportable segment as per the contention of the management.
- Note: 27** Basic and Diluted Earnings per share (EPS) computed in accordance with Accounting Standard (AS) 20 "Earning per Share"

Particulars	31.03.2025 Rs. In Lakhs	31.03.2024 Rs. In Lakhs
<b>Numerator</b> Profit / (Loss) after Tax	27.84	62.07
<b>Denominator</b> Weighted average number of Nos. Equity shares	398624000	398624000
<b>EPS Basic</b> Numerator/Denominator	0.01	0.02
<b>EPS Diluted</b> Numerator/Denominator	0.01	0.02

**Note: 28**

Payment Auditor's	to	2024-25 Rs. In Lakhs	2023-24 Rs. In Lakhs
For Audit		0.30	0.29
For Company Matters		00	00

**Note: 29** previous year figures have been regrouped and recasted wherever necessary.

**Note: 30 Other Notes**

Additional Regulatory Information pursuant to Clause 6L of General Instructions for preparation of Balance Sheet as given in Part I of Division II of Schedule III to the Companies Act, 2013, are given hereunder to the extent relevant and other than those given elsewhere in any other notes to the Financial Statements.

a. During the year ended March 31, 2025 and March 31, 2024, the Company has not advanced or loaned or invested funds (either borrowed funds or share premium or kind of funds) to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding (whether recorded in writing or otherwise) that the Intermediary shall:

- i) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (Ultimate Beneficiaries) or
- iii) provide any guarantee, security or the like to or on behalf of the ultimate beneficiaries.

Further, during the year ended March 31, 2025 and March 31, 2024, the Company has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall: i) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or ii) provide any guarantee, security, or the like on behalf of the ultimate beneficiaries.

b. The Company has not invested or traded in Crypto Currency or Virtual Currency during the year ended March 31, 2025 (Previous: NIL)

c. No proceedings have been initiated on or are pending against the Company for holding benami property under the Prohibition of Benami Property Transactions Act, 1988 (as amended in 2016) (formerly the Benami Transactions (Prohibition) Act, 1988 (45 of 1988)) and Rules made thereunder during the year ended March 31, 2025 (Previous year: Nil).

d. The Company has not been declared Wilful Defaulter by any bank or financial institution or government or any government authority during the year ended March 31, 2025 (Previous year: Nil).

e. The Company has not surrendered or disclosed as income any transactions not recorded in the books of accounts in the course of tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961) during the year ended March 31, 2025 (Previous year: Nil).

f. The Company does not have any transactions with the companies struck off under section 248 of the Companies Act, 2013 or section 560 of the Companies Act, 1956 during the year ended March 31, 2025 (Previous year: Nil).

g. The Company has complied with the number of layers prescribed under clause (87) of section 2 of the Act read with the Companies (Restriction on number of Layers) Rules, 2017.

**Signature to Notes '1' to '30'**  
**As per our report on even date**

**FOR, BIPIN & CO.**  
**CHARTERED ACCOUNTANTS**  
**FIRM NO: 101509W**

**FOR & ON BEHALF OF THE BOARD**

**CA AMIT SHAH**  
**PARTNER**  
**M. No. 126337**  
**UDIN:25126337BMLICR8550**

**AMAN PATEL**  
**Whole Time Director**  
**DIN: 08483544**

**KISHAN NAIDU**  
**Director & CFO**  
**DIN: 08662664**

**PLACE: VADODARA**  
**DATE : 20.05.2025**

**SHREE GANESH BIO-TECH(INDIA)LIMITED**

CIN: L70101WB1982PLC121196

Reg. Office: CUBICLE NO.: 126, 3/2, 75C, PARK STREET, 3RD FLOOR KAMDHENU BUILDING, KOLKATA -700016

Email: shreeganeshbiotechindia@gmail.com Website: [www.shreeganeshbiotech.com](http://www.shreeganeshbiotech.com)**15<sup>th</sup> ANNUAL GENERAL MEETING On 26.09.2025 at 03:00 P.M. at registered office of the company**

Name of the Shareholder:	
Address:	
Registered Folio/ *DP ID & Client ID:	
No of Shares held:	
Name of the Proxy/ Authorised Representative, if any:	

\* Applicable for shareholding in electronic form.

I/We certify that I/We am/are a registered shareholder / proxy for the registered shareholder of the Company.  
I/We hereby record my/our presence at the 14th Annual General Meeting of the Company held on Friday 26<sup>th</sup> September, 2025 at 03:00 PM at registered office of the company.

*Signature of Member/s/ Proxy*

**NOTE:** A member or his duly appointed Proxy willing to attend the meeting must fill-up this Admission Slip and hand over at the entrance.

**PROXY FORM****Form No MGT-11**

(Pursuant to section 105(6) of the Companies Act, 2013 and rule 19(3) of the companies (Management and Administration) Rules, 2014)

CIN	L70101WB1982PLC121196
Name of Company	SHREE GANESH BIO-TECH (INDIA) LIMITED
Reg. Office Address	126,3/2, 75C, Park Street, 3rd Floor, Kamdhenu Building, Kolkata, West Bengal, 700016
Name of the Member	
Registered Address	
E Mail Id	
Folio No./Client ID	

I/We, being the member (s) of SHREE GANESH BIO-TECH (INDIA) LIMITED hereby appoint

Name			
Address			
E mail Id		Signature	

OR FAILING HIM

Name			
Address			
E mail Id		Signature	

OR FAILING HIM

Name			
Address			
E mail Id		Signature	

As my/ our Proxy to attend and vote for me/us on my/ our behalf at the 13th Annual General Meeting of the Company to be held on 26.09.2025. at 03:00 P.M. at registered office of the company and at any adjournment thereof and respect of such resolution mentioned below:

## BALLOT FORM

Resolution No.	Resolution	Nature of Resolution	*Optional	
Ordinary Business			For	Against
01	To receive, consider and adopt the Audited Financial Statements for the Financial Year ended 31st March, 2025.	Ordinary		
02	Re-Appointment of Mr. Aman Patel who retires by rotation	Ordinary		
03	Re appointment of Statutory Auditor of the Company and fix their Remuneration.	Ordinary		
04	Approval for enhancement of borrowing limits of the company under section 180(1)(c) of the Companies Act,2013	Special		
05	Approval for making investments, give loans, guarantees and security in excess of limits specified under section 186 of the Companies Act, 2013	Special		

Signed on this ..... day of .....2025.

Affix  
Re.1  
Revenue

Signature of shareholder ...../ Signature of Proxy .....

### NOTE:

- 1 This form of proxy in order to be effective should be duly completed and deposited at the Registered Office of the Company, not less than 48 hours before the commencement of the Meeting.
- 2 For the Resolution, Explanatory Statement and Notes, please refer to Notice of the Annual General Meeting forming part of the Annual report.
- 3 \*It is Optional to put a 'X' in the appropriate column against the Resolutions indicated in the Box. If you leave

### Route Map to the venue of the AGM

